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Postviral fatigue syndrome is a disorder that follows a 
viral infection and is characterised by severe, 
persistent or relapsing fatigue, usually with myalgia, 
and numerous neuro-psychiatric symptoms (see section on 
clinical features of PVFS).
Many viruses have been implicated in the disorder, e.g. 
Epstein-Earr virus (Hamblin et al, 1983), enteroviruses 
(Bell et al, 1988, Yousef et al, 1988, Miller et al, 
1991), varicella and rubella (Behan et al, 1985). The
main reason for the implication of a putative role of 
viruses in PVFS was that in the original descriptions 
the illness was considered only to occur in epidemics, 
however it is now known to occur as sporadic cases.
a) Historical review of postviral fatigue syndrome:
The first descriptions of the p>ostviral fatigue syndrome 
were made in the eighteenth century and interest in this 
disorder v?as revived in the 1930s when Evans (1947) 
suggested that the syndrome is due to chronic 
brucellosis. Renewed interest in PVFS in the 1950 and 
80s coincided with reports of many epidemics worldwide. 
The last two decades also represent an important 
milestone in the history of PVFS. First, more attention 
has been paid to the sporadic form of the disease and, 
secondly, extensive research programmes to study all 
aspects of this disorder have been established (see 
section on the organic nature of PVFS).
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The first detailed account in the English literature of 
an illness resembling the PVFS was given by Manningham 
more than 240 years ago (Manningham, 1750). The 
disorder, which was known as febricula, was 
characterised by low-grade fever, excessive physical and 
mental exhaustion and fleeting muscle pains. It occured 
mostly in wealthy people, especially females. 
Subsequently, a condition identical to PVFS was 
described in the past century under the name of 
neurasthenia (Beard, 1869). Beard, who believed the 
condition to be organic in nature, stressed that the 
core symptom is physical and mental fatigue and he drew 
attention to the cardiovascular and gast-ro-intestinal 
features of the disease. Ho also confirmed the 
observation of Mannigham (1750) that the illness occurs 
more in females than in males. Two years later DaCosta 
(1871) redescribed the disease under the name “the 
effort syndrome". He emphasised the role of infection in 
intiating the symptoms and documented that the disease 
affects children as well as adults. He also made 
reference to other common features of the syndrome, such 
as palpitations, chest pain, dizziness,
gastro-intestinal symptoms and sleep disturbances.
In the 1930s Evans (Evans, 1947) suggested that the 
disease is a form of chronic brucellosis. However, this 
hypothesis was subsequently challenged as serological 
evidence of continued brucella infection could not be 
demonstrated in most patients (Spink, 1951).
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M a n y e p i d e m i c
1950s and 60s under different names including atypical
poliomyelitis, abortive poliomyelitis Ice landic
disease, Akureyri disease benign myalgic
encephalomyelitis, Royal Free disease, epidemic malaise,
mononucleosis syndrome, chronic fatigue and immune 
dysfunction syndrome. In recent years postviral fatigue 
syndrome and chronic fatigue syndrome have become the 
most widely used names for this condition (Behan &
and, in our opinion, the term postviral fatigue syndrome 
is the most helpful and correct one since it emphasises
disease.
Most of the older literature on PVFS refers to the
epidemic form of the disease. The main epidemics are
summarised in this section (also see table 1/1).
Icelandic epidemic 1948-1949:
This occured in the town of Akureyri (population 6,900). 
6.9% of the population was affected, mostly females
between the ages of 15 and 30 years. There were no
fatalities, but some paralytic cases were reported.
epidemic pseudomyasthenia, chronic infectious
Behan, 1988, Holmes et al, 1988, Sharpe et al, 1991)
the role of viral infections in initiating the
In addition to fatigue, myalgia, especially on exertion, 
was a prominent feature. Nervousness, palpitations and
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excessive sweating were present in 42% and insomnia 
cccured in 15% of patients (Sigurdsson et al, 1950).
Although a causative agent for this epidemic was not 
isolated , poliomyelitis and Coxsackie B viruses were 
suspected. A pandemic of poliomyelitis in 1955 swept the 
whole of Iceland except Akureyri district, which 
suggests that the population in this district had 
developed immunity against poliomyelitis following 
exposure to "epidemic neuromyasthenia" (Sigurdsson et 
al, 1958).
Six years after the Akureyri outbreak only 13% of the 39 
patients studied had recovered completely. In the 
remaining patients the course of the disease was 
characterised by relapses and remissions. Fatigue 
remained the most disabling symptom and most patients 
continued to complain of myalgia, insomnia, nervousness 
and poor memory (Sigurdsson & Gudmundsson, 1956).
The outbreak in Alaska (1954):
Deisher (1957) reported an epidemic of myalgic 
encephalomyelitis in Seward, Alaska, which occured 
several weeks after an outbreak of poliomyelitis. The 
disease predominantly affected young females and was 
characterised by lethargy, muscle pain and stiffness, 
headaches, poor memory, anxiety and depression. 
Paraesthesiae, hyperacusis and photophobia were
- 16 -
prominent features in this epidemic. Interestingly, 
these symptoms increased in severity during menstruation 
and in some patients there was a clear pattern of 
relapses and remissions of symptoms in relation to the 
menstrual cycle.
In contrast to the patients who had developed typical 
poliomyelitis in the previous epidemic, those who 
suffered from myalgic encephalomyelitis had a normal 
cell and protein content in the cerebrospinal fluid and 
viral studies showed low antibody titres against the 
three strains of polio virus.
The Royal Free Hospital outbreak:
This occured in 1955. More than 300 members (or 9%) of 
the staff at the Royal free Hospital in London were 
affected by a flu-like illness. The commonest symptoms 
were fatigue and prostration, sore throats, headaches, 
neck stiffness, dizziness, blurred vision, myalgia and 
depression. Most patients were females (female/male 
ratio was approximately 4:1). Cerebrospinal fluid 
examination was performed in 8 patients and it was 
normal.
Of great interest is a 32 year old female patient who 
was affected in this epidemic (see Crowley et al, 1957). 
This patient. died 7 months a.fter the Royal Free 
outbreak. Postmortem oxmination revealed multiple
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microscopic areas of demye 1 inat. ion in the 
peri-ventricular white matter, brain stem and spinal 
cord. In addition, there was intense lymphocytic 
perivascular infiltration of the hypothalamus. Although 
it is likely that this patient had multiple sclerosis, 
it is unusual for the hypothalamus to be affected in 
this disease and it is possible that these changes were 
related to the "Royal Free Disease". Similar changes in 
the hypothalamus of a patient with PVFS have recently 
been documented at postmortem examination (PO Behan, 
personal communication). A study by Daugherty et al 
(1991) lends indirect support to the hypothalamic 
involvement in patients wit.li PVFS. These authors found 
disseminated white matter lesions on magnetic resonance 
imaging (HRI) brain scans of 15 patients with PVFS. 
However, their findings have to be interpreted with 
caution as they have not yet been replicated.
Shortly after this epidemic 8 sporadic cases of the 
Royal Free disease were reported in North London (Ramsay 
& O'Sullivan, 1956). Although, the occurrence of these 
cases coincided with an increased incidence of 
poliomyelitis in the same area, the disease was 
clinically distinct from polio. There were no paralytic 
cases and the cerebrospinal fluid was normal.
Seven of the eight patients were females. The initial 
symptoms were fever, sore throats, myalgia, anorexia and 
vomiting. All patients had severe fatigue which
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persisted for 4-6 months after the onset of the disease. 
Emotional lability, "mental fatigue" and tinnitus were 
prominent features. Laboratory investigations were all 
normal except electromyography (see under " electro- 
physiological studies) and some non-specific changes on 
the electroencephalogram.
Other epidemics:
Several smaller epidemics of PVFS have been reported 
from various countries. These include an outbreak in 
California, USA, in 1934 (Wilson & Walker, 1936), 
Pennsylvania, USA (McConnell, 1945), Adelaide, Australia 
(Pellow, 1951), Middlesex hospital, London (Acheson, 
1954), Coventry, England (Macrae & Galpine, 1954) and 
many others. The clinical presentation, course and 
outcome of these epidemics were similar to those of the 
Akureyri, Alaska and Royal Free epidemics. In addition, 
a common feature in all of these epidemics is that an 
enterovirus (polio or Coxsakie) had been suspected as 
the cause of the epidemic.
Table 1/1
The main epidemics of postviral fatigue syndrome:
Epidemic year reference
Los Angeles, USA 1934 Wilson & Walker, 1936
HarefieId, 1939
Middlesex, UK
Akureyri, Iceland 1948
.Adelaide, Australia 1949
New York, USA 1950
London, UK .1952
Coventry, UK 1953
Maryland, USA 1953
Berlin, Germany 1954
Royal Free Hosp. 1955
London, UK
Houghton & Jones, 1942
Sigurdsson et al, 1950
Pellew, 1951
White & Burt.ch, 1954
Acheson, 1954
Macrae & Galpine, 1954
Shelokov et al, 1957
Sumner, 1956
Compston, 1956
P e r t h , Au s t r a .1 i a 195! Steen, 1956
Durb Af: 1955 Hill,
20 -
T ah1e 1/1 (c on t i nued)
Epidemic year reference
J o h annesburg,
S. Africa 1954 Jackson et al, 1957
London, UK 1955 Ramsay & O'Sullivan,
1956
Florida, USA 1956 Poskazner et al, 1957
N ewe as11e upon Tyne,
UK 1959 Pool et al, 1961
London, UK 1966 Ramsay, 1978
S.W. Ireland 1976 Corridan, 1978
Southampton, UK 1979 May et al, 1979
Vilest KiIbr ide , 
Sctoland, UK 1980 Fagan et al, 1983
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b ) C1i n i ca1 feat ures o £ PVF3: 
i: the diagnostic criteria of PVFS:
The most important, factor which impeded progress of 
research in PVFG until recently was the lack of a 
universally accepted case definition, making comparison 
of reports by different investigators virtually 
impossible. The recent attempts to lay down guidelines 
for the diagnosis of PVFS (Holmes et al, 1988, Lloyd et
ul, 1988, Sharpe et al, 1991) are a welcome step in the
right direction, although some problems still remain. 
Holmes et al (1988) classified the symptoms of PVFS into 
major, minor and physical criteria. The major criteria 
are:
1. fatigue - which must be persistent or relapsing, not 
improved by bed rest, reducing the patient's activity by 
50% or more and present for six months or more 
.and 2. all other chronic illnesses which might produce 
the same symptoms must be excluded.
There are 11 minor criteria, e.g. myalgia, depression 
and sore throat. The physical criteria are: low grade
fever, nonexudative pharyngitis and palpable cervical or 
axillary lymph nodes. Holmes stresses that both major 
criteria plus either 8 minor or 6 minor and 2 or more 
physical criteria must be present to make the diagnosis 
of PVFS.
In our opinion the working case definition of Holmes et 
al (1988) which is summarised in the previous paragraphs 
has the following weaknesses:
1. in contrast to psychiatric and most other conditions 
which cause chronic fatigue, PVFS is always precipitated 
by a viral infection. The definition of Holmes et al 
(1988) does not take this into consideration.
2. a past or family history of psychiatric illness, a 
poorly-adjusted premorbid personality and a poor work 
record are common in patients with psychiatric disease. 
Although patients with psychiatric illnesses may develop 
PVFS (like anybody else), we feel that patients with 
this history should not be included in clinical trials.
3. The working case definition (Holmes et al, 1983) does 
not include some frequently encountered psychiatric 
symptoms in patients with PVFS such as anxiety and 
hypochondriasis. Furthermore, "prolonged generalised 
fatigue following previucsly tolerable levels of 
exercise" is classified as a minor criterion. We think 
the fact that fatigue is precipitated or made worse by 
exercise is an important characteristic of the fatigue 
in PVFS. In our experience it is present in all patients 
with PVFS. This characteristic should, therefore, be 
incorporated in the definition of fatigue (which is a 
major criterion), rather than relegating it to a minor 
or iterion.
It. Is essential that the criteria used for the case 
dofin*11ion for researc.h purpoge3 are strict, especia. 11 y 
if the disease in question is of unknown aetiology or 
can not bo confirmed with objective laboratory tests, as 
is the case of PVFS. This is important to narrow the 
differential diagnosis, although such restriction will 
inevitably exclude some patients with the disease under 
investigation. In the following section we propose 
alternative criteria for the diagnosis of PVFS.
Our diagnostic criteria incorporate those of Holmes ct 
al (1988) and also the diagnostic guidelines of the 
Medical Research Council (Sharpe et al, 19191). In
addition, t.hese criteria emphasise the important role of 
a viral infection in initiating PVFS and they also 
attempt to exclude patients with possible or known 
psychiatric illness. We have previously published these 
criteria (Behan, 1991, Behan & Bakheit, 1991) which we
s u mm arise below.
1) a history of a definite or probable viral infection 
preceding the onset of symptoms. This history must be 
corroborated by the appropriate laboratory tests;
2) the presence of severe fatigue for six months or more 
which reduced the patient's premorbid level of activity 
by 50% or more. The fatigue is precipitated or made 
worse by physical or mental effort and is not improved 
w .i t h I) e d r e s t;
3) at least three of the following symptoms must be 
present: myalgia, dizziness, sleep disturbances, poor
memory and concentration, anxiety, hypochondriasis, the 
typical depression as described earlier (see section on 
psychiatric symptoms, pages 27-31), early satiety, 
diarrhoea alternating with constipation, abdominal 
bloating, poor appetite, fluctuations in body weight and 
menstrual irregularities;
4) chronic infections, malignancy, autoimmune disorders 
and other medical conditions which may cause fatigue 
must be excluded with the appropriate investigations;
5) patients with a past medical or family history of 
depression or any other major psychiatric illness are 
excluded;
6.) all patients must have a well-adjusted premorbid 
personality (defined as ability to cope with every day 
life stress) and all must have a good work record.
We make the diagnosis of PVFS if the patient fulfils all 
of these criteria.
ii: General symptoms of PVFS:
PVFS occurs in both sexes, but the incidence is higher 
in females. In most series, including ours, 60-70% of 
all. patients were females (Tobi et al, .1982, Jones et
al, 1085, Komaroff & Buchwald, 1991). The disease
affects all age groups. Most patients are between 25-40 
years old. Although children with PVFS may have some 
atypical features (see below), the clinical picture of 
the disease is essentially the same in ail age groups.
The course of the disease is often protracted with 
relapses and remissions occuring at irregular intervals. 
We have seen patients who have had the disease for more 
than 20 years. A chronic relapsing and remitting course 
was also reported in the epidemic form of the disease 
(Sigurdsson l’< Gudrriundsson, 1956, Compston 1956, Ramsay & 
0'Sul1ivan, 1956).
In addition to incapacitating fatigue (see below), 
patients with PVFS have a number of other symptoms which 
occur in various combinations. These include myalgia, 
d is turba i1 ce s o f s1eep, mo o d , memory and concentration, 
gastrointestinal symptoms (see below), fluctuations in 
body weight, excessive sweating, especially at night, 
intermittent low grade fever and headaches. 
Interesingly, the headaches are often of migraine type. 
Recurrent sore throats and cervical lymphadenopathy are 
common. Most patients also complain of tinnitus, 
dizziness, 1ightheadedness, cold extremities and 
sensitivity to bright light and noise. Occasionally, 
acroparaesthesia may be a prominent feature. Some 
patients present with chest pain identical to that of 
Eornnoim d i s eas e (S t ev e ns o n & hambIin, 1971) an d
ischaemic type chest pain may also occur. Indeed several 
of our patients had elaborate cardiological
investigations, including exercise tests and coronary 
angiography. Some of these patients also complain of 
p a ]. p i t a t i o n s.
iii: Fatigue:
Fatigue, as defined by physiologists, refers to a 
progressive decrement in force generation that occurs 
during muscular activity (Lancet, 1988). To the 
clinician fatigue is a state in which a required or 
expected muscle activity can not be maintained (Edwards, 
1078). It is a subjective perception of lassitude or 
lack of energy. In other words, fatigue is "an 
overwhelming sustained sense of exhaustion and decreased 
capacity for physical and mental work" (Piper, 1989).
Two types of fatigue are distinguished: central and
peripheral. Central fatigue occurs in the absence of 
muscle weakness or dysfunction of the neuromuscular 
junction and presumably results from poor motivation 
and lack of drive. On the other hand, peripheral fatigue 
is dire to structural damage of skeletal muscle or the 
neuromuscular apparatus or interference with muscle 
energv me1nboIism.
By definition all patients with the PVFS must have 
fa L igue a s their main complaint. Characteristically, the
2*1
fatigue in these patients is of the "central" type. It 
is persistent or relapsing and does not improve with 
hed rest. It is generally agreed that the fatigue must 
reduce the patient's premorbid level of activity by 50% 
or more (Holmes et al, 1088. Behan & Bakheit., 1991,
Sharpe et al, 1991).
Fatigue is a common symptom in many general medical and 
n eu r o 1 o g i c a .1 conditions. It is c ommo n 1 y reported b y 
patients with bacterial and viral infections, endocrine 
disturbances, e.g. Addison's and Cushing's disease, 
<'acromegaly and hypothyroidism. It is also a frequent 
complaint during pregnancy and the premenstrual tension 
syndrome (Pelosi et al, 1906). Fatigue may be 
troublesome in patients with the irritable bowel
syndrome.
Fatigue is often a prominent symptom, in patients with 
multiple sclerosis and Parkinson's disease and following 
head injuries and stroke.
In multiple sclerosis fatigue was listed as the most 
troublesome symptom by 28% of patients (Krupp et al, 
1988, Krupp et al, 1989). In a third, of these patients 
fatigue preceded other symptoms of the disease and 
p-atients described their fatigue as qualitatively 
different from that experienced before their illness. 
Interestingly, fatigue* in multiple:* sclerosis was found 
to be independent of the presence or absence of
depression and it. affected both males and females.
F a t i g u e i. s a 1 so c o m m o n i n patients w ith Parkins o n ' s 
disease. Like fatigue in multiple sclerosis, it is also 
of the "central" type and may be, at least in part, due 
to the diurnal fluctuations of nigro-striatal dopamine 
concentrations (see Critchley et al, 1991). Fatigue and 
sleep disturbances are also present in patients with 
encephalitis lethargica and other parkinsonian syndromes 
which follow viral infections such as rubella, mumps and 
po 1 i omye 1 i t i s .
iv: Sleep disturbances in PVFS:
Sleep disturbances have been reported in all epidemics 
of PVFS. For example, in the Akureyri epidemic 16% of 
patients had severe insomnia (Sigurdsson et al, .1950). 
Disorders of sleep are also common in the sporadic form 
of the disease and occur in 15-90% of patients (Komaroff 
& Buchwald, 1991).
Three patterns of sleep disturbances are observed in 
patients with the PVFS. In adults the most frequently 
reported sleep abnormality is that of excessive sleep. 
Patients usually go to sleep early and stay in bed for 
10 hours or more. The sleep is not fully refreshing and 
patients often have difficulties with concentration 
during the day. A similar pattern of sleep disturbances 
has been reported in patients with the premenstrual
- 29 -
tension syndrome and seasonal affective disorder (SAD) 
which are probably associated with central 5-HT 
abnormalities (Wurtman &. Wurtm&n, 1989). A smaller group 
of .adult patients with PVFS suffer from insomnia, whilst 
the commonest form of sleep dicturbaces in children is 
reversal of sleep pattern with insomnia at night and 
hypersomnolence during the day.
v: Psychiatric Symptoms:
Psychiatric symptoms are frequently encountered in 
patients with PVFS. These include poor concentration and 
memory, anxiety, irritability, hypochondriasis and 
depression. The reported incidence of these symptoms 
varies from 50 to 90% (Behan et al 1985, Straus, 1988, 
Komaroff & Buchwald, 1991).
The multiple symptomatology and the paucity of abnormal 
physical signs in patients with PVFS has led to the view 
that the syndrome is a somatisation disorder in patients 
with predisposition to psychiatric illness, especially 
depression (Cluff, 1991). The issue is complicated 
further by two other factors. These are:
a) the significant overlap between the symptoms of PVFS 
and those of depressive illness (Crowley et a.1, 1957, 
Behan & Bakhe.it, 1991, Thase, 1991);
b) the heterogeniety of the depressive syndromes.
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Although pat.lento with PVFS share a number of symptoms 
with those suffering from major (primary) depressive 
illness, there are also important differences. According 
to the current diagnostic criteria of the American 
Psychiatric Association (1987) a diagnosis of major 
depressive illness is made when the patient has a 
depressed mood and at least four of the following 
symptoms:
1. markedly diminished interest or pleasure in all or
most activities;
2. 5% or more change in body weight in a period of 4 
weeks. Increase or decrease in appetite;
3. sleep disturbances, characteristically insomnia and
early morning waking;
4. psychomotor agitation or retardation;
5. feelings of guilt or worthlessness;
6. suicidal ideation or a recent suicidal attempt;
7. poor concentration/ indecisiveness;
8. fatigue.
In contrast to patients with major depressive illness, 
those with PVFS do not experience guilt or feelings of 
worthlessness, nor do they heave suicidal ideation, 
hallucinations, delusions, psychomotor agitation or 
retardation. In our experience, these patients are 
capable of experiencing pleasure and continue to have 
i nt er e s t i n a11 th e i r h obb i e s and 1eisure a c t iv i t i e s, 
i.e. they remain hedonic (Behan & Bakheit, 1991). Our
observations are in agreement with results of a recent 
study which showed that depressive symptoms in patients 
with PVFS are indistinguishable from those seen in 
patients with chronic rheumatoid arthritis (Procter, 
1991). Anhedonia was not reported by patients in either 
group. Hypochondri a s i s is usually present in most 
patients with PVFS. Interestingly, this symptom is not 
regarded as a diagnostic criterion for major depressive 
illness (American Psychiatric Association, 1987).
The heterogeniety of the depressive syndromes is 
illustrated by the complex classification of these 
disorders. In addition to major depressive disorder, the 
third (revised) edition of the Diagnostic and 
Statistical Manual of Mental Disorders (American 
Psychiatric Association, 1987) distinguishes another two 
less severe conditions in which a depressed mood is a 
prominent feature. These are: adjustment disorder and
dysthymic disorder. The first condition is characterised 
by a depressed mood plus one or two of the symptoms 
listed above. If these symptoms persist for 2 or more 
years, the condition is named dysthymic disorder. The 
Association also recognises a group of unclassifiable 
depressive disorders.
To define the psychiatric symptoms in patients with PVFS 
more clealy we have studied 57 patients with PVFS and 19 
healthy control subjects. The two groups were matched 
for age, sex, socio-economic status and level of
education.
Mood (affective state) was assessed using standard 
questionnaires. Depression, anxiety and physical 
symptoms were measured using the Middlesex Hospital 
Questionnaire (Crown & Crisp, 1966), the Spielberg State 
Anxiety Inventory (Spielberg et al, 1970) and the 
Cohen-Ilobermann Index of Physical Symptoms (Cohen & 
Hobermann, 1983), respectively. The Cognitive Failures 
Questionnaire (Broadbent et al, 1.982) was used to 
document the self-reported errors of memory, attention 
and action. In addition, a battery of performance tests 
which have been previously used to assess the effects of 
acute viral infections on memory, attention and 
psychomotor function were performed (Smith et al, 1987, 
Smith, 1990). These were variable-fore-period simple 
reaction time, five choice serial response, detection of 
repeated numbers, free recall, delayed recognition 
memory, digit span, logical reasoning and semantic 
processing tasks. To measure distractability the stroop 
colour-word test was used (Smith & Broadbent, 1985).
Analysis of the self-rating questionnaires showed that 
patients with PVFS reported significantly higher levels 
of depression and anxiety compared to control subjects. 
As expected, they also had more physical symptoms . The 
psychomotor tests revealed that patients with PVFS were 
slower than control subjects in retrieval of information 
from general knowledge (semantic memory task) and
working memory (logical reasoning task). They also had 
problems maintaining attention and showed increased 
sensitivity to visually disturbing stimuli.
In an attempt to establish the effects of depression on 
the cognitive deficits mentioned above patients with 
PVFS were divided into two groups: those with low or
high levels of depression. Comparison between the two 
groups showed similar impairments in patients with high 
and low levels of depression. This indicates that the 
mental impairments in patients with PVFS are independent 
of depression.
As stated earlier, the characteristics of depressive 
symptoms in patients with PVFS are distinct from those 
of primary depressive illness. Anhed.onia, hallucinations 
and delusions, feelings of guilt and self-depreciation, 
•which are the hallmark of major depressive illness, are 
not reported by patients with the PVFS. Nevertheless, it 
has been argued that PVFS represents a somatisation 
disorder in subjects with a premorbid vulnerabilty to 
depression (Taerk et al, 1987). This hypothesis was 
based on the finding of an increased prevalence of 
life-time psychiatric illness in patients with. PVFS in 
comparison to control subjects. However, methodological 
bias accounts for this finding as the reported diffrence 
between the two groups disappears when only the 
premorbid psychiatric events are considered. Two recent 
s t u d i e p. o f c a r e f u 13. y s e 1 e c t e d g r o u p s of patients w 3. t h
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PVFS and control subjects did not demonstrate a 
significant difference in the prevalence of premorbid 
psychiatric illness between the two groups (Hickie et 
al, 1990, Procter, 1991).
vi: Gastrointestinal symptoms in patients with PVFS:
Abdominal bloating, nausea and early satiety are common 
symptoms of PVFS. In our series of 287 patients 55% 
complained of gastrointestinal symptoms, an incidence 
wh 5ch i o s imilar to th a t re po r t e d by E om a r o f f a nd 
Buchwald (1991). We have seen some patients in whom 
these symptoms are accompanied by diarrhoea which 
alternated with constipation. The clinical picture in 
these patients is identical to that, of the irritable 
bo'wel syndrome .
The clinical similarities between PVFS and the irritable 
bowel syndrome are intriguing. Indeed the two disorders 
nay share a common pathogenetic mechanism. In a recent 
study Dinan and collaborators (Dinan et al, 1990) have 
shown that the symptoms of the irritable bowel syndrome 
(also known as the syndrome of non-ulcer dyspepsia) may 
be due to dysfunction of central 5-HT neurones. Using 
the buspirone challenge test (see chapter two), these 
authors have demonstrated a significantly greater’ 
prolactin response to buspirone in patients with the 
irritable bowel syndrome than in healthy control 
subjects or patients with pept i c ulcer disease. This
observation suggests hypersensitivity of hypothalamic 
5--HT receptors and is similar to our findings in 
patients with PVFS which are dicussed in the following 
chapters.
Several of our patients reported craving for chocolate 
and sweets which they did not have prior to their 
illness. Interestingly, craving for carbohydrates is 
known to occur in patients with seasonal affective 
disorder and also in women with the premenstrual tension 
syndrome (Wurtman & Wurtman, 1989).
vii: The effects of menstruation on the symptoms of
PVFS:
Menstruation exacerbates ail symptoms of the PVFS. 
Deisher (1957) noted that myalgia, fatigue, fluid 
retention and irritability markedly increased in female 
patients immediately before menstruation. Interestingly, 
these patients had never experienced premenstrual 
tension before the onset of PVFS. In seme patients the 
exacerbation of symptoms at mid cycle was so severe and 
occured with such regularity that a pattern of relapses 
and remissions in relation to menstruation was clearly 
recognisable by the patient. Similar observations have 
been reported by other investigators (Leon-Sotomayor, 
19G9, Behan & Bakheit, 1991). The exacerbation of PVFS 
in mid cycle appears to be a common complication. 50-60% 
of patients with PVFS in one series had this
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comp lie at ion ( Komaroff & Eraehwaid, 1991).
The mechanism by which menstruation causes exacerbation 
of the symptoms of PVFS is not clear. Studies in the rat 
have shown that hypothalamic 5-HT receptors undergo 
regular functional changes during the? oestrous cycle 
being up-regulated following ovulation (Biegon et al,
1980) and it is possible that a similar mechanism 
accounts for the exacerbation of PVFS in humans (see 
following sections).
v.i i : Sympt oms in chi 1 dren:
PVFS is less common in children than in adults. Bell et 
al (1991) have found that the risk of developing the 
disease is higher in children with an allergic disorder 
or a family history of autoimmune disease and also in 
those who have an adult family member with the disease.
Although the symptoms of PVFS in children and adults are 
essentially the same, there are some differences between 
the two groups. For example, the psychiatric symptoms of 
PVFS are more prominent in children than in adults. 
Patients are usually tearful and very dependent on their 
mothers. Eating disorders are also more frequently 
encountered in chi Idem than in adults with PVFS. The 
problem is usually that of anorexia rather than 
overeating. Finally, sleep disturbances in children are 
characterised by reversal of sleep- pattern with insomnia
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during the night and excessive sleep during the day 
(Behan & Bakheit, 1991).
c) Conditions with some clinical resemblance to PVFS:
The clinical features of PVFS closely resemble those of 
the fluid retention syndrome (FRS) and the premenstrual 
tension syndrome (PMT), suggesting a common pathogenetic 
mechanism for these disorders.
The fluid retention syndrome (also known as cyclic 
oedema and idiopathic oedema) is a relatively common 
disorder of unknown aetiology. The diagnosis is based on 
t} i e p r es eno e o f the foilowing three features: f luid
retention, autonomic and psychiatric symptoms (Dunnigan, 
1991). In addition, fatigue may be a prominent complaint 
(Pelosi et al, 1986) and symptoms* of the irritable bowel 
syndrome are frequently reported (Dunnigan 1985). The 
psychiatric symptoms include depression, irritability, 
poor memory and concentration and sometimes anxiety 
(Pelosi et al, 1986).
The pathogenesis of FRS is not fully understood. 
Although previous studies did not demonstrate 
abnormalities in the levels of circulating hormones 
(Smith et al, 1972), more recent evidence points to a
possible dysfunction of the hypothalamic-pituitary axis 
in patients with this disorder. For example, the 
syndrome often occurs in obese women and abnormalities
of glucose metabolism, such an insulin resistence or 
frank diabetes, are common in patients and their 
r e1a t i ve s (Dunn i gan, 1990). Mild dysfunct i on o f the
thyroid gland may be present in some of these patients 
(Al-Khader & Aber, 1979). Furthermore, abnormal levels
of circulating prolactin and sex hormones have been 
documented in these patients (Young et al, 1983).
PMT is a disorder characterised by variable increase in 
body weight, bloating, abdominal colic, mastalgia, 
excessive fatigue, mood swings, and sleep disturbances. 
In contrast to FRS, PMT reccurs regularly in the same 
phase of the menstrual cycle and the patient is 
invariably completely symptom-free postmenstruum.
PMT frequently occurs in patients with migraine 
(Tindall, 1987), a condition which is associated with 
central 5-HT abnormalities. It has been shown that 
fluctuations of 5-HT levels occur in the different 
phases of the menstrual cycle and that the observed 
changes correlate with behavioural abnormalities which 
occur in some women in mid cycle (Rausch & Janowsky, 
1982). More recently Rickels et al (1989) have shown 
that buspirone, a 5-HT receptor agonist (and also a 
partial dopamine receptor antagonist), enhances 
prolactin release in patients with PMT but not in 
control subjects. Furthermore, buspirone alleviated the 
symptoms of PMT in these patients. These findings 
suggest a relationship between PMT and abnormalities of
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5HT secretion or dysfunction of central 5HT receptors 
and are similar to our findings in patients with PVFS 
which are described in chapter 5.
Many patients with PVFS complain of increase in body 
weight and exacerbation of their fatigue and other 
s y m p t om s p r e m e n s t r u a 11 y . In at 1 e a s t. f o u r of o u r 
patients the severity of premenstrual bloating and 
peripheral oedema was similar to that of the classical 
FRS (Behan & Bakheit, 1991). The following case history 
illustrates the- clinical overlap between PVFS, FRS and 
PMT.
Case history:
The patient is a 44 year old married branch manageress 
with British Telecom who had not worked since the onset 
of her symptoms seven years ago. Her main symptoms are 
excessive fatigue and lethargy, depression, poor memory, 
excessive sleep (12-14 hrs/day), joint and chest pains, 
abdominal bloating, diarrhoea alternating with 
constipation, intermittent swelling of the hands and 
feet and weight gain. Her body weight fluctuated by two 
stones within a few days and this coincided with periods 
of severe depression and weepiness. These symptoms are 
worse premenstrua1ly.
The symptoms followed an attack of hepatitis A which she
d e v e loped wh i .1 e i n G a mb i a . The course of her illness was
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initially characterised by re lap sere and remissions 
lasting several weeks. However, two years ago she 
developed herpes zoster, following which she did not 
enjoy any further remissions.
There was no past medical or family history of note. She 
is a non-smoker and does not drink alcohol.
General physical and neurological examination was 
entirely normal. A full blood count, serum urea and 
electrolytes., liver and thyroid faction tests were 
normal. The erythrocyte sedimentation rate was 26 mm in 
the first hour. So rum elec t r o pi i o r e s i a showed the Igli to 
be slightly depressed but was otherwise normal. CSF cell 
and pro to in content were normal. Function of the 
pituitary-hypothalamic-adrenal axis -was normal. Barium 
studies of the gastrointestinal tract and a chest X ray 
were normal (interestingly the patient was diagnosed by 
a general physcian as having the irritable bowel 
syndrome). The buspirone challenge test and measurements 
of total body water in the follicular and luteal phases 
of the menstrual cycle were grossly abnormal (see 
chapters three & four). A needle muscle? biopsy from 
vastus lateralis of the quadriceps femoris 'muscle 
revealed type two fibre atrophy. No viral particles were 
detected in muscle biopsy with the polymerase chain 
reaction using an enterovirus-specific probe.
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e } The organic nature of PVFS:
As discussed earlier, chronic fatigue is a common 
complaint. In one study fatigue was reported as the main 
complaint by 25% of patients attending a primary care 
clinic (Kroenke et al, 1988). Fatigue is also common in 
psychiatric patients. As many as 15% of those with 
somatisation disorders complain of incapacitating 
fatigue (White, 1989). Controversy about the organic 
nature of PVFS (for examples see Imboden et al, 1961, 
Swartz, 1988, David et al, 1988, Cluff, 1991) has arisen 
because of three reasons. Patients with PVFS seldom have 
physical signs on clinical examination and 
a.t present there are no simple laboratory (i. e. 
objective) methods which can confirm the diagnosis in 
these patients. An additional problem is the overlap of 
symptoms of PVFS and major depressive illness, e.g. 
depressed mood, anxiety and hypochondriasis. In this 
section wo summarise the currently available evidence 
for the organic nature of PVFS.
i: Viral studies:
As discussed earlier, reviews of epidemics of PVFS, as 
well as studies of sporadic cases show that the disease 
is precipitated by viral infection. Several serological 
studies have demonstrated higher Coxsackie B or 
Epstein-Barr viral titres in patients with PVFS than in 
the control populations but this may be only a
reflection of high background infection in the community 
(Millor et al, 1991). Furthermore, rises of antibody
titres. in response to viral infections have been shown 
to vary depending on ago and gender (BIggar et al,
1981). The yield from viral culture of faeces and body 
fluids is relatively small. Enteroviruses were isolated 
(after removal of neutralising antibodies) from only a 
quarter of patients with PVFS (Yousef et al, 1988). Only 
recently the use of more reliable? markers of viral 
infection has been introduced as a research tool in 
patients with PVFS. These include mollecular 
hybridization techniques and the polymerase chain 
reaction.
Using an enterovirus group-specific probe, Archard et 
al. (1988) were able to detect enterovirus RNA particles 
in 26 out of 111 muscle biopsies of patients with PVFS. 
None of 30 healthy control subjects was positive. The 
authors suggested that persistence of infection may be 
an important pathogenetic mechanism of muscle 
fatiguability in these patients.
As shown by a study In this department (Gov; et al, 1331) 
the polymerase chain reaction is a more sensitive method 
of detection of viral RNA than mollecular hybridization 
techniques. In this study muscle biopsy material 
obtained from the vastus lateralis of the quadriceps 
femoris muscle of 60 patients with PVFS was studied with 
trie polymerase chain reaction. An enterovirus-specific
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RNA probe was used. Enteroviral genomic RNA was detected 
in 32 out of 60 biosies (53%). This contrasts with a 23% 
detection rate with mollecular hybridization methods 
(Archard et al, 1988).
We extended the observations of Gow et al (1991). Since 
publication of the original report, we have studied 
another group of patients with PVFS with the polymerase 
chain reaction using the same enterovirus-specific 
probe. Needle muscle biopsy material was processed in 
the same way as in the previous study. Of 61. patients, 
28 were positive for genomic RNA and in 33 patients the 
virus particles were not detected with the polymerase 
chain reaction. These findings show that despite the 
sensitivity of the polymerase chain reaction, virus 
particles are not detected in almost half the patients 
with PVFS. However, it must be realised that other 
viruses, such Epstein-Barr, varicella zoster and rubella 
virus may also be associated with PVFS. It is also 
possible that the distribution of viral particles in 
muscle is patchy and that the needle biopsy may not be 
representative.
ii: Immunological studies:
Various immunological abnormalities have been reported 
in patients with PVFS but there is some lack of 
consistency between reports. For example, Kibler et al 
(1985) have demonstrated depressed in vitro production
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of lyrnphokir.es in patients with PVFS but other workers 
did not agree (Straus et al, 1989, Behan & Bakheit,
1991), This may be due to bias in the selection of 
patients. In recent years two abnormal immunological 
findings have been well-documented: increased
circulating immunoglobulins and decreased function of 
natural killer cells (Caligiuri et al, 1937, Murdoch, 
1988, Morrison et al, 1991, Buchwald et al, 1991).
In this regard, Morrison, Behan and Behan (1991) 
studied the function of natural killer cells in 23 
patients with PVFS and 19 age and sex-matched healthy 
control subjects. Using fluorochrotne-conjugated specific 
monoclonal antibodi.es, these authors found a reduction 
in the numbers of CD56- and an. increase in CD56-t- natural 
killer cells in patients with PVFS in comparison to 
control subjects. There was also a decrease in CD16+ 
cells (CD56+ Fc gamma receptor bearing cells) which 
suggests a reducxed antibody-dependent cellular immunity 
in these patients. A previous study of natural killer 
cells function in patients with chronic fatigue 
following Epstein-Barr virus infection has also 
demonstrated low natural killer cell cytotoxicity in 
these patients (Caligiuri et al, 1937).
As many as 50% of patients with PVFS give a history of 
atopy and allergic conditions and a similar history can 
often be elicited in these patients' relatives ( Olson 
et al, 1986). Several of our patients also have
re1atives w 11h PVFS.
i: Genetic studies in PVFS:
The familial clustering of cases of PVFS and a high 
incidence of atopic disorders in these patients and 
their relative O vl n 0 well documented. Deisher (1957) 
found a high frequency of multiple cases in the same 
household during the epidemic of myalgic 
encephalomyelitis in Alaska and similar findings were 
reported in the Royal Free Hospital (Crowley et al, 
1957) and Akureyri epidemics (Sigurdsson et al, 1950). 
More recently, Bell et al (1991) reported seven cases of 
PVFS occuring in two families. Wo have also seen the 
disease affecting more than one member of the same 
family in at least three occasions.
A history of atopy in patients with PVFS and their first 
degree relatives is common. 21 out of 187 consecutive 
cases of PVFS admitted to our unit had a past or a 
family history of an allergy or an atopic disorder. The 
incidence of these disorder was reported to be between 
40 and 70% by other investigators (Komaroff & Buchwald, 
1991, Bell et al, 1991).
In order to examine the possible role of genetic factors 
in the pathogenesis of PVFS we studied the HLA 
expression in a well-defined group of 41 patients with 
this disorder (17 males and 24 females). 500 healthy
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subjects from the same area were used as controls. We 
did not find any differences in HLA-A, HLA-B and IILA--DR 
antigen frequencies between patients and controls. 
However, in about a third of our patients HLA-DK antigen 
typing was not possible because of poor viability of B 
lymphocytes in patients with PVFS. We believe that the 
poor viability of B lymphocytes in our patients is due 
to some inherent property of these cells rather than due 
to methodological artefacts, as there was no delay in 
processing the blood samples. Interestingly, a recent 
study from South Africa has also demonstrated abnormal 
KLA-DR antigen expression in 3 out of 10 patients with 
PVFS (van Greune & Bouic, 1990). Thee significance of
these findings is at present not clear and more research 
in this field is required.
iii: Abnormalities of skeletal muscle mitochondria in
PVFS:
In a study of 60 muscle biopsies of patients with PVFS 
morphological abnormalities of skeletal muscle were 
found in the majority of patients (Gow et al, 1991, Gow 
& Behan, 1991). Light microscopy revealed non-specific
type two fibre atrophy in 50 out of 60 patients. Ragged 
red fibres, i.e. aggregates of mitochondria seen on 
light microscopy when the tissues are stained with 
Gomori trichrome stain, were also present in most cases. 
In 7 5 % of patients electron microscopy showed that the 
mitochondria were pleomorphic, swollen and vacuolated.
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In addition, there was obvious ,,compartnentalisationM 
a.nd x-'’ro 1 iferat.ion of cristae (Figure 1 /1) ,
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Figure 1/1
Mitochondrial abnormalities in skeletal muscle of 
patients with PVFS.
a) Patient with postviral fatigue syndrome. Skeletal 
muscle biopsy showing increased number of enlarged and 
pleomorphic mitochondria in the subsarcolemma1 and 
intermyofibrillar regions, x 7,800
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Figure 1/1
b) Same patient as in figure 1/1 a. Greatly enlarged and 
pleomorphic mitochondria showing proliferation of the 
cristae (’’compartmentalizat ion” ) . Five normal sized 
mitochondria are also present, x 78,000
iv: SI ec 1 rophyo ii o 1 ogica 1 stud ies :
Ramsay and O'Sullivan (1956) carried out
electromyographic (EMG) studies in 8 patients suffering 
from the Royal Free disease. Although the EMG findings 
were essentially normal, these authors found a reduced 
number of motor unit potentials, i.e. reduced
interference ’pattern. In addition, the motor units were 
of long duration, p>olyphasic and often of large 
ampli tudo.
In a later study of single fibre electromyography (Jamal 
& Hansen, 1966) abnormal jitter values were demonstrated 
in 75% of patients with PVFS. A subsequent study 
replicated the findings of Hansen & Jamal in four out of 
30 patients studied (Roberts, 1990). This low incidence 
of jitter abnormalities in this group may be due to bias 
in patients'' selection. In contrast to patients with 
myasthenia gravis and other neuromuscular disorders, 
impulse blocking has not been reported in patients with 
PVFS.
v : Metabolic studies in patients with PVFS:
The excessive muscle fatigue and, myalgia of PVFS (which 
are characteristically precipitated or made worse by 
exercise) suggest an abnormality of intermediate muscle 
metabolism. This possibility was Investigated by a 
number of authors.
A study of muscle metabolism with nuclear magnetic 
resonance spectroscopy in a patient with PVFS (Arnold et 
al, 1984a) revealed an abnormally early intracellular 
acidosis during exercise which was out of proportion to 
high energy phosphate metabolism.
Lactic acid may accumulate in the cell for one or more 
of the following three reasons:
a) reduced cytoplasmic buffering capacity;
b) impaired elamination of acid from the cell;
c ) defec ts of the regu 1 ation. of the relative 
contribution of glycolytic and oxidative processes in 
muccle enorgy provis ion.
Arnold and colleagues argued that neither reduced 
cytoplasmic buffering capacity, nor the impaired 
elemination of acid from the cells were responsible for 
their findings because the pH did not continue to fall 
as the intensity of exercise increased and also'because 
the rate of pH recovery after exercise was normal. These 
authors suggested that the observed abnormality of 
muscle energy metabolism in PVFS is due to a disorder of 
metabolic regulation. The same investigators documented 
similar observations in a further group of patients 
with PVFS and postulated that persistence of virus in 
skeletal muscle may be responsible for the observed 
abnormalities (Arnold et al, 1984b, Taylor, 1989).
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Riley et al. (1990) used a symptom limited exercise 
treadmill test paradigm to evaluate the aerobic work 
capacity in 13 patients with PVFS, 13 healthy control 
subjects and another group of controls consisting of 7 
patients with the irritable bowel syndrome. The aerobic 
work capacity was assessed using clinical and laboratory 
criteria, such as heart rate, length of time on 
treadmill (an indication of fittness and exercise 
tolerance), serum lactate, blood glucose, creatine 
kinase, oxygon consumption and gas exchange before and 
at regular intervals during the test.
Patients with PVFS had a significantly higher heart 
rates at submaxima 1 levels of exercise4 and also higher 
serum lactate concentrations than the control groups. 
These findings show that patients with PVFS have a 
reduced aerobic work capacity in comparison to controls. 
Furthermore, these patients perceived the work load at 
peak exercise to be greater than did the control 
subjects. In this study the end tidal C02 concentration 
was normal at the begining and also at peak exercise 
which rules out the presence of hyperventilation in 
these patients.
Chapter two
HYPOTHALAMUS AND 5-HYDROXYTRYIYT AMINE
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a) Hypothesis and aims of the study:
The symptoms of PVFS were described in the previous 
chapter. They suggest dysfunction of brain structures 
which control circadian rhythms, food intake, water 
balance, gut motility, temperature regulation, cardiac 
function and mood and emotions. The control of all of 
these functions is regulated by the hypothalamus, and 
thus we undertook a study of hypothalamic function in 
patients with PVFS.
The hallmark of PVFS is overwhelming persistent or 
recurrent fatigue. As described in chapter one, the 
fatigue in this disorder is due to lack of central drive 
and is similar to that reported in patients with 
multiple sclerosis (Krupp et al, 1988) or Parkinson's 
disease (Critchley et al, 1991).
In addition to integration of visceral and endocrine 
function, the hypothalamus also influences drive, mood 
and behaviour. The control exerted by the hypothalamus 
on visceral and brain structures is mediated mainly via 
5-HT and dopamine (see below). In theory, therefore, all 
the symptoms of PVFS could be explained by hypothalamic 
dysfunction. In an attempt to test this hypothesis we 
studied different aspects of hypothalamic function in a 
well-defined group of patients with PVFS. In this study 
we assessed the functional status of hypothalamic 5-HT 
receptors and evaluated the water metabolism and
melatonin secretion in these patients.
b) Structure and function of the hypothalamus:
The hypothalamus is a small structure situated below the 
hypothalamic sulcus. The anterior border of the
hypothalamus is formed by the optic chiasm. Posteriorly 
it is bounded by the mamillary bodies. The median 
eminence of the hypo thalamus forms the floor of the 
t h i r d v e n t r i c 1 e .
Three groups of hypothalamic nuclei can be 
distinguished. These are:
1) the anterior group, i.e. the supraoptic and 
p a r av e n t r i cu1ar nuclei;
2) the middle group which consists of the tuberal,
arcua t e, vent r omed i a1 and v ent ro1at e r a1 nuclei;
3) the posterior group.
The hypothalamus has extensive reciprocal fibre 
connections with all brain structures, including the
cerebral cortex, the limbic system and brain stem. It
also has a strong anatomical relationship with the 
pituitary gland by means of neural pathways and a system 
of portal blood vessels (Brodal, 19S9).
Hypothalamic 5-HT receptors:
5~hydroxyt.ryptam.ine (5-HT) or serotonin is a ubiquitous
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nourotransmitter. 90% of the total body 5-HT is
contained in the chromaffin cello of the small intestine 
and most of the remaining neurotransmitter is present in 
blood platelets. Less than 5% of the total body 5-HT is 
f o u n d i n b r a i n .
5-HT neurones, as mapped by immunocytochemical methods, 
are cluster red along the midline in the pons and upper 
brain -stem (raphe nuclei), the area postrema, locus 
ceruleus and around the interpeduncular nucleus.
Neurones of the raphe complex are the main source of 
brain 5-HT. Fibres from the raphe medianus largely 
project to limbic structures, whereas cells of the 
dorsal raphe complex send their fibres to the 
neostriatum, cerebral and cerebellar cortex. The 
hypothalamus receives serotoninergic fibres from the 
raphe complex. In addition, about 30% of hypothalamic 
5-HT is produced locally by neurones and a group of 
specialised ependymal cells of the third ventricle 
(Brownstein et al, 1976, Erownstein, 1981).
Research in 5-HT receptor pharmacology is a rapidly 
advancing field and, although an attempt has been made 
to give a comprehensive review of the literature, this 
account is unlikely to be up to date in a few months' 
t ime.
in man •hree different types o: -Hr r e c e p t o r s h a v e
boon identifled so far and preliminary evidence suggests 
a possible fourth receptor type (Montgomery &. Finberg, 
1989). These are designated 5-HTI, 5-HT2, 5-HT3 and
5-HT4 receptors. 5-HT receptors are further subdivided 
into 5-IIT1A, 5-HT1B, 5-HT1C and 5-HT1D subtypes (Bradley 
et al, 1986, Conn & Sanders-Bush, 1987). This
classification is based on the anatomical 
distribution of these receptors, their possible
physiological function and the selective binding of 
1igands to the diffront receptor subtypes (see table 
2/1). These receptor subtypes are present in brain and 
peripheral tissues, principally in platelets and smooth 
muscle of the gut and blood vessels.
5--HT1A receptors, in brain arc mainly presynaptic and are 
present o n  n e r v e terminals that release 
neurotransmitters other than 5-HT, e.g. dopamine, 
acetylcholine etc. Their function appears to be the 
control of release of these neurotransmitters. 5-HT1A 
receptors are also found in the internal carotid artery 
and its branches (Lancet, Editorial, 1989). 5-IIT has an 
inhibitory action on all 5-IIT 1A receptors. Thus, it 
causes vasodila tat i on and increases intestinal 
Ps ristalsis.
5-HT1B receptors have been described in rodents (Conn i 
Sanders Bush, 1987). However, those receptors have no-
yet been found i n human br a i.n.
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Brain 5-HT2 receptors are either inhibitory or 
excitatory and are probably responsible for most of the 
central effects of 5-HT. In the periphery these 
recejptors are excitatory and their activation leads to 
contraction of smooth muscle in blood vessels and gut 
and also causes platelet aggregation. In brain these 
receptors are abundant in the hippocampus and frontal 
cortex (Hoyer et al, 1985). To date there are no
selective drugs which act on these receptors. Ritanserin 
(which has agonist action on 5-HT2 receptors) also acts 
on dopamine receptors.
5-HT3 receptors are localised in the limbic system and 
gut. These receptors are indirectly involved in 
behaviour, memory and emotional responses. Barnes and 
collaegues (Barnes et al, 1989) have shown that 5-HT 3 
receptor antagonists enhance cholinergic transmission in 
the limbic system which is essential for memory 
formation and retrieva1 (Deutsch, 1971).
Despite the major advances in 5-HT receptor pharmacology 
in recent years, the pharmacological manipulation of 
these receptors has clinical application in only a few 
disorders at present. For example, 5-HT antagonists such 
as pizotifen and methysergide and more recently the 5-HT 
reuptake inhibitor, sumatriptan are used in the 
treatment of migraine, while cyproheptidine and 
o n d a n s e t r o n (PI a 11 e t a 1, 19 92) are e f f e c t i v e i n.
reliefing the symptoms of the carcinoid syndrome. In
both cases these drugs' beneficial effect is achieved by 
blocking the peripheral actions of 5-HT. Interference 
with central 5-HT receptors with buspirine has been 
shown to be useful in the treatment of anxiety states 
(Cohn et al, 1986) and the premenstrual tension syndromes 
(Rickels et al, 1589).
In addition to the therapeutic use of drugs acting on 
5-HT receptors, some of these agents, e.g. buspirone and 
motergolino, are now ’widely used to study the functional 
activity of 5-HT receptors in different psychiatric 
disorders. In this study wo used buspirone to assess the 
hypothalamic 5-HT receptors in patients with PVFS. The 
rationale for using this agent is din cussed in a later 
section.
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T a b l e  2 / 1
Properties of 5-HT receptor subtypes:
Receptor 
5-HT1A
5-HT1B+* 
5-HT10
5-HTID
5-HT 2
5-HT 3
agonist 
8-0HDAP* 
buspirone 
sumatri ptan
mosulengine 
metergoline 
mianserin 
ergot alkaloid: 
sumatriptan 
ritanserin 
ketanserin 
ICS 205-930*+*
antagonist 
not available
pisot ifen 
m e thysergide 
ondansetron 
granisetron
* 8-hydro:-:y-N , N-dipropy 1-2-aminotetralin
+ '*•' 5-HT1B receptors have not yet been found in 
brain.
* * * 3-alpha-t r opanyl-lH -- i n d ole- 3-carboxyl ic ester
human
Functions of the hypothalamus:
Until relatively cen the function of the?
hypo tha Iannis was thought to he limited to the
integration and control of autonomic funct and the
gulation of the
gland (Brooks, 1988). However, in recent years a wider 
role for the hypothalamus in neuroendocrine regulation 
has been appreciated and three more functions have been 
recognised. It is now well established that the 
hypothalamus is involved in emotional expression and 
adaptation to stress, consolidation of short term memory 
and also immune regulation.
i: The autonomic functions of the hypothalamus:
Experimental studies and clinical observations show an 
important role for the hypothalamus in the regulation of 
food intake and fluid balance. Ishibashi and collaegues 
studied the effects of neuropeptides on the feeding 
behaviuor in animals. These authors have shown that 
direct application of thyrotropin releasing hormone 
(Ishibashi et al, 1979a) or cholecystokinin (Ishibashi 
et al, 1979b) on ventromedial hypothalamic neurones of 
the rat has an anorezogenic effect. Similar observations 
wore reported in patients with hypothalamic disease. 
For example, destruction of the lateral hypothalamic 
nuclei by tumours has been reported to cause a syndrome 
identical to anorexia nervosa (White & Hain, 1959,
Strieker & Anderson, 1980;, Weller & Weller, 1982). By 
contrast, bilateral lesions of the venteromedial nucleus 
lead to hyperphagia and gross obesity (Reeves & Plum, 
13G9, Beal et al, 1981). Intrestingly, Kleine-Levin 
syndrome (Levin, 1936), which is characterised by 
hypothalamic hypogonadism, obesity, hyperphagia and 
increased somnolence, is thought to be due to 
hypothalamic dysfunction during puberty (Critchley, 
.1962). More recently, Carpenter et al (.1.982) have found 
.inflammatory changes in the hypothalamus of a patient 
with this disorder. This is in accord with a previous 
postmortem report of a patient with a ventromedial 
h ypo th&d am i c neoplasm who presented with hyperphagia, 
behavioural changes and memory impairment (Reeves & 
Plum, 1969).
Hypothalamic-pituitary regulation of water balance:
50-60% of the total body weight of an adult is water. 
The total body water content is 5-10% more in females 
than in males. This depends largely on the differences 
in body fat content between the two sexes. Extracellular 
fluid (plasma, CSF, gastro-intestinal juices etc.) 
constitutes a third of the total body water content. The 
remaining two thirds is contained in the intracellular 
space. This ratio is kept constant thanks to the 
continuous fluid shifts between the extra and 
intracellular fluid copmartment 3 . S imilarly, the total 
body water content is maintained within a narrow range
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by achieving a balance between fluids intake (via the 
thirst mechanism) and water loss, e.g. in urine and 
sweat. Water homeostasis is regulated by the 
hypothalamic-pituitary axis via the release of the 
antidiuretic hormone arginine vasopressin and the thirst 
mechanism.
Arginine vasopressin:
Arginine vasopressin (AVP) is a nonapepti.de which is 
synthesised and released by the posterior lobe of the 
pituitary gland, i.e. the neurohypophysis. This hormone 
selectively increases the permeability of the collecting 
ducts of the nephron to water, thus enhancing the back 
diffusion of solute-free water. The end result of this 
effect is the production of concentrated urine.
The synthesis and release of AVP is regulated by a group 
of cells in the anterior hypothalamus known as the 
osmoreceptor. Immunocytochemical studies have shown that 
the perikarya of these neurones are the large cells in 
the supraoptic, and paraventricular nuclei and the small 
cells in the dorsal pole of the suprachiasmatic nuclei 
of the hypothalamus (Gainer & Erownstein, 1981, Thasher, 
1985). Fibres from these neurones project to the 
posterior lobe of the pituitary gland via the supraoptic 
hypophysial tract.
Hypothalamic osmoreceptors regulate AVP release in
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response to changes in plasma osmolality. In addition, 
they are a 1 so sens itive to a number of other stimuli, 
including nausea (Rowe et al, 1979), cigarette smoking 
(Rowe et al, 1980), hypoglycaemia (Bay!is et al, 1981) 
and some drugs, e.g. histamine, acetylcholine and 
catecholamines. Changes in the circulating blood volume 
also influence the sensitivity of the osmoreceptor via 
pressure sensitive; receptors in the heart and the large 
blood vessels (Robertson, 1987).
Changes in the osmotic gradient across the cell membrane 
is the most potent stimulus of the osmoreceptor. 
Increase in plasma osmolality per se does not have any 
effects on the hypothalamic-pituitary axis. For example, 
a rise in osmolality due to a permeable solute such as 
urea does not stimulate AVP release, whereas impermeable 
solutes (sodium, mannitoi) are potent stimuli for AVP 
secretion (Vok.es et al, 1987).
Although a one per cent change in plasma osmolality is 
sufficient to cause changes in circulating AVP 
concentrations, only a fall in plasma osmolality to 280 
mosmol/kg or an increase to 295 mosmol/kg is considered 
a critical threshold for the functional "set" of the 
osmoreceptor (Kovacs & Robertson, 1992). At a plasma 
osmolality of 280 mosmol/kg the; plasma AVP is often 
undetectable and the urine flow rate increases to its 
maximum (>10 inl/min) to prevent further dilution of body 
fluids. The opposite changes occur when plasma
osmolality approaches 295 mosmol/kg. These are 
summar ise d be 1 ov; (t ab 1 e 2/1) .
Table 2/1
Plasma osmolality thresholds which alter the functional 
"set" of the osmoreceptor:
Plasma osmol urine osmol AVP thirst urine flow rate 
mosmol/kg mosmol/kg pmol/1 ml/min
280 <100 v. low/ no >10
u n d o t c- c t ab 1 e
295 >800 0.5-7 yes <0.5
The thirst mechanism:
The group of hypothalamic neurones which trigger thirst 
are adjacent to but completely distinct from those 
responsible for the regu.lt ion of AVP synthesis and 
release (Hammond et al, 1986). It is not surprising that 
the thirst "centre" responds to the same stimuli as the 
osmoreceptor. However, the osmotic threshold "which 
triggers thirst exceeds that for AVP release by 10-15 
mosmol/kg (Robertson, 1983). In other words, a healthy 
subject feels thirst only when the plasma osmolality 
exceeds 310 mosmol/kg.
The hypothalamus also plays an important role in the 
regu1ation of circadian rhythms, including
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.le ep-v/akefu.1 ness cycles and reproduction in all animal 
ipecies (Shilling et al, 1986) and also in man (nee
oeiow
ii: Memory and emotions:
Thanks to the close anatomical relationship of the 
hypothalamus with all parts of the limbic system, this 
organ plays an important role in the regulation of 
function of limbic structures. The hypothalamus receives 
ex t ensive fibre connectio n s f r cm 1i mb ic structures, i n 
particular the amygdaloid and septal complex and sends 
fibres to the brain stem and cerebral cortex, thus 
linking the ]imbic system to the reticular formation and 
cerebral cortex (Swanson & Sawchenko, 1983, Steriade Sc
L1i nas, 19 8 8, Guy to n , 1991).
Studies of the physiological responses to emotional 
stress have shown that expression of these responses in 
man consists of three inter-related reactions (Folkow, 
1.988). These are a situation-specific behaviuoral 
response, a soniato-motor and an autonomic response. 
These responses are associated with metabolic and 
endocrine changes which provide the optimal milieu for 
the behavioural expression and are regulated by the 
hypotha1amus.
In addition, the hypothalamus appears to have a more 
direct influence on human and animal emotional
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reactions. For example, stimulation of the anterior 
ventral group1 of hypo th a 1 am i c neurones in man evokes 
f ear and anxiety (Monroe & IIeath, 1954.) , whi 1 st 
stimulation of po s t e r o-me d i a1 neurones causes 
c bs ea s io n a1 b ehavi our (S a no, 1975). S t imulation of the 
lateral hypothalamus increases the animal"s general 
activity. The opposite occurs with stimulation of the 
med i a1 nuc1e i (Givens, 19S 4).
ili: Immune regulation and the hypothalamus:
The hypothalamus regulates the function of the immune 
system by two mechanisms. First, by exerting modulating 
influences on the limbic system and, secondly, by 
directly controlling the function of the sympathetic and 
puraoympathetic systems.
The negative effects of severe emotional trauma on the 
human defence mechanisms and resistence to infections 
are well known. For examine, it has been shown that 
bereavement is associated with transient impairment of 
function of T lymphocytes and increased susceptibility 
to infection (Bartrop et al, 1977). Sustained emotional 
stress may also increase the risk of disease by 
decreasing the numbers of circulating lymphocytes (Spry, 
1972). In addition to these effects (which are probably 
mediated via the limbic system), experimental evidence 
suggests that the hypo th a1amu s has a direct influence on 
immune regulation. Lesions of the anterior hypothalamic
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nuclei have been shown to inhibit antibody production 
(Tyrey & Nalbandov, 1972) and decrease anaphylactic 
reactione (Schiavi et a1, 1975).
iv: The regu1ation of neuroendocrine function:
Monoamine neurotransmitters and neuropeptides such as 
corticotropin releasing hormone and cholecystokinin 
(Ishibashi et al, 1979b) have been shown to mediate the
function of hypothalamic neurones. In animal studies 
t h e io c a 1 a pp J i c a t i o n o f n o r a. d r e n a I i n e (C a 1 oger o et al, 
ID88a) or acetylcholine (Calogero et al, 1988b) onto the 
hypothalamus caused the secretion of corticotropin 
releasing' hormone, whereas the application of gamma 
aninobuteric acid resulted in the opposite effect 
(Calogero et al, 1988c).
A detailed review of the effects of various 
neurotransmitters on neuroendocrine regulation is beyond 
the scope of this thesis. In this section we briefly 
summarise the effects of those neurotransmitters which 
influence prolactin release.
The control exerted by the hyopthalamus on pituitary 
lactotrope cells is mediated mainly by two different 
neurotransmitters. These are 5-HT and dopamine.
Hypothalamic 5-HT fibres have been implicated in the 
contrc1 o f var i ous hypothalamic func t ions (Kato et a 1, 
1974) as well as the stimulation prolactin (Lamberts &
DVJ ..
MaeLoed, 1973) and growth hormone* release (Roland! et 
al, 1992). By contrast, dopaminergic neurones inhibit
prolactin release. Administration of specific dopamine 
agcni st o , o . g . bromocr iptine and apornorphine (Mac Loed
k Lehmeyer, 1974) suppresses prolactin release. On the
other hand, drugs which deplete dopamine (reserpine, 
methyldop'Q, etc) or increase 5-HT concentrations (e.g. 
tryptophan) stimulate prolactin release. Similarly, 5-HT 
antagonists such as methysergide and metergoline 
(Gregory et al, 1990) block prolactin release. Thus, the 
u s e of ph a r maco 1 o g ical a g o n t s v? i t h s p e cif i c off e c t s o n 
hypothalamic 5-HT or dopamine receptors and the serial 
measurements of serum prolactin concentrations may 
provide an accurate in vivo method of functional 
assessment of hypothalamic neurones.
c) The use of neuroendocrine challenge tests in the 
s t udy o f h ypo tha 1 am i c fu n c t i o n :
The family of drugs known as the azapirones are 
well-tolerated agents which cause the release of 
prolactin, ACTH, cortisol and growth hormone via the 
selective stimulation of pre- and postsynaptic central 
5-HT1A receptors (Tuomisto & Mannisto, 1985). These 
drugs include buspirone, gep.irone and ipsapirone. The 
selectivity of the azapiror.es has been disputed. For 
example, McMillen et al (1983) have suggested that 
buspirone stimulated prolactin release by blocking 
dopamine receptors, while Meltzer and Fleming (1S82)
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} i a v e d c m o n 31 r a f, e d in i x e d d o p a m i n e a g o n ist-a 111 agon i s t 
properties for buspirone. Another complicating factor is 
chat in brain the azapirones metabolise to a piperazine 
d e r i v a t i v e w i t h a 1 ph a 2 a d r e n e r g i c receptor a a t a g o n i s t 
properties (Caccia et al, 1986). However, it is unlikely 
that the effects of the azapi rones are mediated via 
adrenergic receptors. This is because 5-HT1A receptor 
antagonists such as Pindolol (Ccccaro et al, 1990, Cowan 
et a 1, 1990 ) and metergo 1 ine (Gregory et al, 1990 )
abolish the plasma prolactin increase produced by 
buspirone. Further evidence suggests that prolactin 
release is mediated by 5-HT pathways and is independent 
of dopaminergic function. For example, chemical or 
surgical destruction of central 5-HT ixathways inhibits 
prolactin release} (van de Kar & Bethea, 1982). The 
prolactin releasing effect of fenfluramine can bo 
abolished by pretrcatment with trie 5-HT antagonist, 
cyproheptidine (Lewis 5 Sherman, 1985). Similarly, 
ritanserin (5-HT2 receptor antagonist) inhibits 
prolactin release in females whose dopamine 2 receptors 
wore blocked by sulpiride (Falaschi et al, 1989). 
Although buspirone has effects on both dopaminergic and 
5-HT receptors, the current evidence suggests that the 
prolactin response to buspirone is largely mediated via 
5-HT1A reoeptors .
The azapirone most widely used in psycopharmacology
research is buspirone. Following oral administration of 
this drug the serum pro! etc tin levels rise in a
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dose-depen dent inch ion raid reach their peak one hour 
after the dose (Seppala et al, 1987). This effect was 
not observed with chronic administration of therapeutic 
doses of buspirone to healthy subjects or patients with 
anxiety (Tollefson et al, 1989).
The administration of a single oral dose of buspirone 
and serial measurements of serum prolactin is now 
accepted as a simple and reliable method of studying 
central 5-HT receptors. As discussed earlier, the 
symptoms of PVFS suggest hypothalamic dysfunction. Many 
Patients with PVFS suffer from conditions such as 
migraine, fluid retention syndrome and the irritable 
bowel syndrome in which 5-HT metabolism is known or 
suspected to bo abnormal (see chapter one). This is 
suggestive of a common underlying pathogenetic mechanism 
for all of these disorders. We decided, therefore, to 
study the function of hypothalamic 5-HT neurones in a 
well-defined group of patients with PVFS and compared 
them with healthy control subjects and patients with 
Primary deprescive illness.
d) The pineal gland and melatonin:
Study of the pineal gland and its hormone melatonin may 
give important clues as to the pathogenesis of PVFS. 
Experimental evidence suggests that melatonin has 
effects on sleep regulation, alertness, mood and gonadal 
function. The effects of th e diurnal variations of
plasma melatonin concentrations on fatigue are also well
documented.
The pineal gland is the main site of melatonin synthesis
and release (Lesnick et al, 1985) . It also has ; it
highest concentration of 5-HT in brain (Browns te-in, 
1981, Vaughn, i98i). The synthesis and release of
melatonin is regulated by the h y po th a1amu & via two 
neural circuits: fibres from the superior cervical
gang] ion and the re t i no--hypo thalam.i c tract (Moore , 1970 , 
Moore h Kl.i.r-n, 1984).
Tin? main sites of action of melatonin are thought to be 
the hype th a 1 a muz and brain stein. These areas have the 
highest density of melatonin receptors as shown by 
radioactive melatonin uptake studies (Anton-Tay & 
Wurtman, 1969, Bittman & Weaver, 1990).
Current evidence suggests that the effect of melatonin 
on hypothalamic neurones is mediated via 5-HT 
re1e a se. F o r ex amp1e , an int r ape r i t o ne a1 injection of 
melatonin results in a rapid rise in brain 5-HT 
concentrations (Fraschini et al, 1971), whereas direct
infusion of melatonin into the pituitary gland has no 
effect (Kamberi et al, 1971). In the rat subcutaneously 
injected melatonin binds matin ly to hypothalamic neurones 
(Lang et al, 1981). Furthermore, 5-hydroxyindoleacetic 
acid: 5-HT ratio (an index of 5-HT turnover) in
hypotha1amic neurones of blinded hamsters Is increased
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(Vriend, 1989), suggesting an important role of
hypotha 1 amic 5--HT neurones in the control of behaviour 
mediated via the photonsuroendocrine system.
Melatonin and sleep:
Under physiological conditions darkness increases 
endogenous melatonin secretion and induces sleep (Sander 
et al, 1972, Wetterberg, 1978). The reverse is also true 
(Hansen et al, 1979). Similarly, administration of 
melatonin to healthy subjects (Anton-Tay et al, 1971,
Armstrong et al, 1982, Arcndt et al, 1985a) and to 
patients with chronic insomnia (Bock-Friis et al, 1984, 
L i eb e rman e t a 1, 19 8 4 ) i nduc e s s 1 e e p .
Melatonin and mood:
In 1979 Wetterberg and co-workers drew attention to the 
possible effects of melatonin on mood when they
demonstrated abnormal melatonin levels in a patient with 
major depressive illness (Wetterberg et al, 1979). 
Subsequently, a strong correlation was found between the 
incidence of depression and the relatively short hours 
of day light in winter, while hypomania occured mostly 
in the spring as the day lengthened (Weller & Jauhar, 
1981, Parker & Walter, 1982, Rosenthal et al 1984).
Furthermore, high plasma melatonin levels in hypoman.ic 
patients and low concentrations in patients with
depression have been reported by many investigators (for
eview see Checkley & Arendt, 1984).
v: Melatonin and endocrine function:
The role of melatonin in animal reproductive physiology 
has been known for many years (see Lincoln, 1983). In 
humans melatonin delays the onset of puberty and 
inhibits the maturation of sex organs and pineal tumours 
may cause sexual precocity (Ringerts et al, 1954, Martin 
A Reichlin, 1987). Variations in plasma melatonin 
concentrations throughout the menstrual cycle have also 
been reported (Wetterberg et al, 1976).
Me1a t on i n and fatlyue:
A close correlation between the incidence and severity 
of fatigue in healthy subjects and changes in the 
concentration of urinary melatonin has been established 
(Wetterberg, 1970). A similar relationship between 
fatigue and disruption of melatonin, circadian rhythms, 
e.g. following air travel over several time zones (jet 
lag syndrome) or when light-darkness cycles were 
increased or decreased under experimental conditions, 
has also been reported (Arendt & Marks, 1982, Arendt et 
al. 1985a) . Interestingly, the fatigue of the jet lag 
syndrome can be alleviated by manipulating the circadian 
rhythms with exogenous melatonin (Arendt et al, 1986).
MATERIALS AND METHODS
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Ma t e r i a 1 s & me t.ho cl s
As can be seen from the preceding discussion, all the 
symptoms of PVFS could be explained as due to 
hypothalamic dysfunction. We therefore devised a set of 
three experimental studies to test various aspects of 
this part of the central nervous system. The experiments 
were:
Experiment 1: study of the functional status of
hypothalamic 5--HT neurones
Experiment 2: study of water metabolism, including the
total body water in patients and arginine-vasopressin 
secretion. Two patients with PVFS who had severe fluid 
retention were also studied during the various phases of 
the menstrual cycle
Experiment 3: study of melatonin excretion 
Materials:
Selection of patients:
The following criteria were used in making the diagnosis 
of PVFS:
1) the symptoms of PVFS wore preceded by an acute viral 
ilinec s in a11 pat i ent s.
2) all patients had fatigue for at least six months and 
the level of fatigue was such that it reduced the 
patient's premorbid level of activity by 50% or more. 
The fatigue in these patients is made worse by exercise 
and is riot affected by bed rest
3) in addition to the typical chronic fatigue, patients 
had three or more of the following symptoms: myalgia,
sleep disturbances (insomnia, excessive sleep or 
reversed sleep pattern), depression, excessive sweating, 
constipation alternating with diarrhoea, palpitations 
and unsteadiness, menstrual irregularities and minor 
fluctuations in body temperature.
4) lack of co-morbidity: none of the patients had
clinica 1 or 1 aboratory ev.idence of chironic i 1.1 nesses , 
e.g. infection, ma1i gna ncy, auto-immune disease, 
metabolic or endocrine disturbances.
5) none of the patients had a past or family history of 
a major psychiatric illness and all patients had a good 
work record and a well-adjused premorbid personality as 
shown by the patients' previous ability to cope with 
everyday life stress.
In addition to these strict diagnostic criteria, an 
objective confirmation of the organicity of the 
patients' illness was sought. All patients but one had a 
needle muscle biopsy from the vastus lateralis of the
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quadriceps femoris muscle. The biopsy was processed for 
routine and electron microscopy and also for detection 
of genomic RNA sequences using the polymerase chain 
reaction.
Experiment 1: study of hypothalamic 5-HT receptors in
patients with PVFS:
Patients and control subjects:
It) consecutive patients admitted to the Institute of 
Nourological Sciences between January and June 1991 for 
the diagnostic work-up of postviral fatigue syndrome 
gave an informed consent to participate in the study. 
There were 9 males and 6 females. The mean age of males 
was 39.8 yrs (range 29-59) and that of females was 33.1 
yrs (range 25-40). The demographic characteristics of 
these patients are given in table 3/1.
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Tabl a / j.
7'he demog raphie charac teris tics of patients with '
!\ fS; "» sex d ui'1 a tion of PVFS p.c.r* mitochondria
(yrs ) (yr3) damage**
Co jijh M OO - 4“ 4-
•79 M 10 + -
59 M o*d« - 4-4-
49 M 5 - 4-4-
42 M o - 4- +
32 M 1 + +
30 M 4 4-4-
29 M 1. 5 -i -
45 M 2 ■f 4-4-
20 F o 5 ... 4-
39 F 3 + 4-4-
40 F 6 NA NA
20 F 1. 5 4- -
25 F 2 4- -
3 9 F 9 - 4-
* P- C . V il P 0  
1 _i mera.se chain reaction
■+* + = mild, 4-4- = moderately severe mitochondrial damage 
NA = data not available
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The control subjects consisted of two groups - a group 
of healthy volunteers and another one of patients with 
primary depressive illness. The healthy volunteers were 
recruited from the laboratory staff. There were 7 males 
and 6 females. The mean age of males was 36 yrs and that 
of females was 30.6 yrs.
The group of patients with primary depressive illness 
consisted of 7 males and 6 female3 with a mean ago of 35 
and 31.1 yrs, respectively. Depressive illness was 
diagnosed according to the DSM-III-R criteria (American 
Psychiatric Association, 1937.) and all patients had a 
Hamilton depression score of more than 20 (Hamilton, 
1960).
Mono of the patients or control subjects was taking any 
medication for at least six weeks prior to the study. 
Female patients who were menstruating normally were 
studied during the luteal phase of the menstrual cycle 
(see diccuscion).
Methods:
Patients and control subjects were fasted overnight. At 
8:30 am the following morning a canula was inserted into 
the anticubital vein of the non-dominant arm and a blood 
sample for baseline prolactin levels was taken 15 
minutes later. Subjects were then given a single oral 
dose of 60 mgs of buspirone at 9 am. Further blood
samples were collected hourly for three hours. Subjects 
remained in the recumbent position during the test.
Prolactin levels were measured blind to diagnosis by 
immunometric assay. Assays were standardised against 
NX BSC Third International Standard 84/500. The within 
and between batch co-efficient of variation were 3% and 
6%, respectively over the concentration range 2 0 0  to 
3000 mU/1.
The response to buspirone was determined by subtracting 
baseline from peak prolactin levels and the latter value 
was expressed as a percentage of base].ine prolactin. For 
reasons discussed later the data for males and females 
w e r e a n a 1 y s e d g q p e r a t e 1 y.
The statistical analysis of data was performed using 
Minitab Statistical Software (release 7.2).
Experiment 2: study of water metabolism in patients with 
PVFS:
i: The pilot study
We carried out a pilot study in which patients with PVFS 
were challenged with the water loading test under 
standard conditions as described by Robinson et al. 
(1941) and Suffer b Gabrilove (1952).
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Vs selected 3 patients with PVFS and 8 healthy control
subjects for this study. The patients and control
subjects were matched for body weight. The patients"
selection was based on the diagnostic criteria described 
above. All patients had evidence of mitochondrial damage 
consistent with PVFS (see chapter one) and enteroviral 
genomic RNA was detected with the polymerasg chain 
reaction in muscle of these patients. There wore 3 male 
an d 6 f e m a 1 e p a t i e n t s. Th e me a n a g e f o r m ales w a s 3 8 . 6  
and that of females was 34.3 years. The control group 
consisted of 4 males and 4 females with a mean age of 27 
and 26 years, respectively. All patients and control 
subjects had normal blood urea and electrolytes and a 
random blood glucose recruit. Hone of the patients or 
control subjects was taking any medication for four 
weeks prior to the study. Smoking was not allowed for 
the duration of the study.
All subjects fasted from mid night. At 8 am the
following morning they wore asked to empty their 
bladders and the urine passed was discarded. The body 
weight of each subject was then recorded. Subjects were 
then given 2 0 ml/kg body weight of tepid water to drink 
over 45 minutes. To eleminate the effects of posture and 
exorcise on urine excretion the test was carried out 
with subjects in the recumbent position. However, they 
were allowed to sit or stand up when voiding. Urine was 
collected hourly for four hours.
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Patients with PVFS excreted 64. G ± 8.2% (mean ± SD) of 
the water load, compared to 36.9 ± 26.2% in healthy
control subjects (raw data in tables 3/2 & 3/3). The 
difference be tween the two groups is statistically 
significant (Student's t test, p < 0.01). We therefore 
decided to study water metabolism in greater detail in a 
well-defined group of patients with PVFS.
The study consists of three parts. In the first part we 
measured the total body water content in nine randomly 
selected patients with PVFG. For the second part of the 
study wo identified two female patients with PVFS who 
exhibited features of the fluid retention syndrome. 
Water metabolism in these .patients was studied at 
various stages of the menstrua], cycle. In the third part 
of the study we evaluated the hypothalamic-pituitary 
regulation of vasopressin release in patients with PVFS 
using the water loading and water deprivation tests. 
D 0 1 a i 1. s o f t h e s o s t u d i. e s a r e n o w d escribed.
rn-i-.'] p 3 / 2
Water loading t e s t in nine pathonto with
Patier;it age o e x duration, of P V F S  %
( y r s ) (y r s ) w a
1x. • 4 1 Id' 5 6 3
2 . 3 9 F 1 5 5 6
o
4 9 M 1 0 6 9
‘"i . 3 6 F 9 7 0
5. 2 9 M 9 G O
G . 4 5 F 4 5 0
7. 3 8 M 2 7 3
a. 2 4 F 1 7 5
p. 2 1 F o 6 6
urine output of
Table 3/3
Water loading test in 8 healthy control subjec
ubj . age water load urin
(yrs) (ml.) of wate
- 30 M 1,350 96. 2
‘7 30 F 2 ,0 0 0 93.7
o 26 17 1,350 111.4
4 n o ^ u M 1, 400 81.4
1) 24 F 1 , 0 0 0 107
R 24 F 1, 500 115
7 26 M 1,400 40.7
I) 24 m 1,625 125'
output
load
— G D ~
.1 i : measurement of total body water and total body
Po t a s s ium i n pat i o n 1 s w ith PVFS:
Patients: 9 patients with PVFS gave an informed consent 
to take part in this study. There wore 4 males and 5 
females. The demographic characteristics of these 
patients are given in table 3/4.
Methods: Total body water was measured by tracer
dilution in plasma samples taken 4 hours after an oral 
dose of 4 MBq Initiated water as described by Poon et al 
(1989). The measured values were compared with published 
predicted values based on height, weight, age and sex 
(Ckrabal et al, 1973).
Total body potassium was measured using a whole body 
monitor to assess the body content of the naturally 
occuring radio-isotope of potassium, i.e. potassuim 40. 
The scanner type whole body monitor has sodium iodide 
detectors and is calibrated to take account of the 
differences in radiation absorption by subjects of 
va.ryi.ng size and body fat content (Runcie & Hilditch, 
1974). The measured values were also compared with 
predicted values available from standard charts (Boddy 
et al, 1372).
— p
Table 3/4
The demographic characteristics of patients selected for 
measurements of total body water and potassium content
Patient age(yrs) c* o tv- height(cm) weight(kg)
i 6 6 M 160.5 67.0
o 19 M 184.0 65.5
o
vJ - 57 M 176.5 76.5
/I-± . 27 M 168.5 72.4
r.•j - 37 F 150.5 51.9
6 . O Q flu KJ F 169.5 61.9
7 45 ]7 159.0 49. 1
e. 4 4 }? 159.0 06.4
n . 27 F 162.5 r,n o
ill: study of total body water content in female
patients with PVFS and severe symptoms of fluid
retent ion:
For this part of the study we selected two female 
patients with PVFS (not included in .the first part of 
the study) who exhibited gross features of fluid 
retention. The case history of one of these patients is 
given in. page 39. The second patient is a 46 year old 
v;oman who had PVFS for 10 years.
Baseline total body water, total body potassium and
glomerular filtration rate were measured in these
patients in the follicular and repeated in the luteal 
phase of the menstrual cycle using the methods described 
above. In addition, the extracellular and intracellular 
water content were also measured in the first patient in 
both phases of the menstrual eye I.e. In the second 
patient it was possible to measure these values only in 
the follicular phase of the cycle because of technical 
difficulties. The results are expressed in the standard 
way as percentage of the predicted values.
iv: study of arginine-vasopressin release in patients
with PVFS:
Patients: nine patients with PVFS and eight healthy
control subjects gave an informed consent to participate 
in the study. The demographic characteristics of
89 -
patients and. controls are given in table 3/5. The 
diagnosis of PVFS was based on the criteria described 
above.
Table 3/5
Viator loading and water deprivation tests: the
demographic characteristics of patients with PVFS and 
c on tro1 sub j e c t s.
Patient s contro1s
bales 4 4
Females 5 4
mean age (yrs) 38.3 26.5
mean duration of illness 6 . 2 yrs
Methods:
Arginine-vasopressi n (AVP) secretion in response to 
changes in plasma osmolality was assessed using the 
water loading and water deprivation tests.
Water loading test:
Patients were fasted from mid night and at 8 a.m. the 
following morning their body weight was recorded and a 
canula was inserted into the antecubital vein of the 
non-dominant arm. A blood sample for baseline 
me asurements of blood urea and electrolytes, blood 
glucose and plasma AVP was then taken. Baseline plasma 
and urine osmolality were also measured. Subjects were 
then given 2 0 ml/kg body weight of tepid water to drink
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over 30-45 minutes; urine and blood samples were then 
c o 11 e c t e d h o u r 1 y f o r f o u r h o u r s.
Water deprivation test:
This 'was carried out on a. separate day. Patients were 
fasted from mid night till 3 pm the following day. 
Samples for urea and electrolytes, plasma, osmolality and 
AVP and urine osmolality were taken at 9 am and every 
two hours thercafter.
Urine and plasma osmolality were determined by 
depression of freezing point. Blood samples for AVP 
assay were centrifuged at 4 °C within 30 minutes of 
venesection and were stored at - 7 0 °C. Because AVP binds 
t o p1a telets (Pro ibisz ct a 1 , 198 3), the p1 asma
immediately above the sediment was not removed. The 
plasma AVP was measured by the immunoassay method 
described by Morton et al. (1985).
Experiment 3: study of me la. ton in excretion in patients
with PVFS:
Patients and control subjects:
Eight patients with PVFS (2 males and 6 females) and six 
age and sex-matched control subjects (2 males and 4 
females) were recruited for the study. Patients with 
PVFS were selected according to the diagnostic criteria 
d e s c r I b e d e a r 11, e r . Th e c on t r o 1, s ub j e e I: s w e r e pa t i e n t s
v.f t.l; v.vioiio neiuv>logioal condit.i on. a. All control 
'i tfoci o o; ;i!ip 1 a .i nod of excessive fatigue but none of 
1 1 ion had a viral illness in the six months preceding the 
study. hone of the patients or control subjects was on 
any medication during or at least four weeks prior to 
the study. The demographic characteristics of patients 
and control subjects are given in table 3/5.
Tab le 3/
Mela ton!n in PVFS: the demographic character1st:
pat lento wl th PVFS and 6 control subjects.
•O--. -i- L CA L>lento with PVFS:
Mo age sex duration of PVFS (yrs)
1 A r\ F
o 40 F 4
o 28 F 1.5
,1-i 46 M 6
5
6
35
34
F
F
*7
1
*7 44 M oo
Oo 29 F
Control subjects:
Mo age sex diagnosis
1 55 F mixed connective tissue disease
o 47 M pro?: ima 1 myopathy
O 34 T? Possible muItiple sclerosis
‘i 47 F non-metastatic breast carcinoma
5 39 M spastic paraparesis ? cause
6 o2 F multiple sclerosis
Methods
Patients and control subjects were admitted to hospital 
for the duration of the study. They fold owed their 
normal daily routine and were allowed to go to bed 
whenever they wished to do so. Urine for melatonin 
measurements was collected continuouslv every four hours 
for 48 hours. The amount of urine passed every four 
hours was recorded and then a 2 0 ml sample was taken, and 
the rest of urine was discarded. The urine samples were
V
stored immediately after collection in -70 C until 
analysed.
Urine was analysed for G-sulphatoxy melatonin using the 
immunoassay method described by Arendt et al (1385b). 
6 -sulphatoxy melatonin is the main metabolite of 
melatonin and its concentration in urine correlates 
closely with plasma melatonin levels (Matthews et al, 
1991). Thus, measuring urinary 6 -sulphatoxy melatonin 
concentrations over a period of time is as reliable as 
serial plasma melatonin estimations in evaluating pineal 
function. In addition, it has the advantage of being 
more convenient for patients than plasma sampling.
The urinary melatonin excretion over each 4 hour period 
in day one was added to that of the corresponding £>eriod 
in day two and the sun was divided by two to obtain the 
mean urinary melatonin excretion for that period. The 
urinary melatonin excretion in patients with PVFS was
-  94 -
then compared with that of control subjects using 
analysis of variance for repeated measures (ANOVA).
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CHAPTER FOUR
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Re suIts
a ) B Li c p i r o n e c h all e n g e t, e s t:
All patients and control subjects completed the study 
s a t i s f a c t o r i 1 y . Th e a dm i. n i s t r a t i o n o f bus p i rone caused 
excessive fatigue and 1 ightheadednoss in patients but 
n o t i n t h e c o n t. r o 1 g r o ups.
Electron microscopy of muscle biopsy showed
mitochondrial changes similar to those previously 
described in patients with PVFS (Cow et al, 1990) in all 
patients studied and RNA enteroviral sequences were
detected with the polymerase chain reaction in 6
patients.
The mean prolactin values before and after the oral
administration of 60 mgs of buspirone are given in 
-tables 4/1 & 4/2 and are graphically shown in figures 
4/1 and 4/2. Summary statistics are shown in tables 4/3 
and 4/4.
Teak prolactin values occured at one hour in patients 
with PVFS and in female patients in the control groups 
and at two hours in healthy and depressive males. As 
shown in table 4/1 and 4/2 there was no statistically 
significant difference in baseline prolactin values 
between patients with PVFS, healthy individuals and 
patients with primary depressive illness. Similarly, 
comparison between patients with PVFS and each of the
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control groups did not reveal a statistically 
significant difference (PVFS vs healthy subjects: p =
0.6 for males and 0.09 for females, PVFS vs depressives: 
P  = 0.9 and 0.2 for males and females, respectively), 
however, the percentage difference between peak and 
baseline . prolactin levels was significantly higher in 
patients with PVFS than in healthy control subjects and 
patients with primary depression (see table 2/6). There 
was also a statistically significant difference when 
patients with PVFS were compared with each control . group 
separately (PVFS vs healthy subjects: p = 0.02 for males 
and 0.01 for females, PVFS v g  depressives: p ~ 0.01 for 
males and 0.004 for females).
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Table 4/1
Prol a ctin r espouse (mtJ/ L) to 60 rN* of buspirone :
healthy males, 7 male pat ients with ]primary depres
illness and 9 male patients with PVFS:
Nc baseline 1 9 3 hrs differenc
Healthy control subjects:
1. 90 199 186 144 .121
2. 151 364 4.92 286 225
3. 21.2 512 501 476 141
.112 436 473 475 342
5. 160 320 310 1.80 1 0 0
6 . 220 460 456 381 109
7. 1.96 396 290 282 1 0 2
Patients with depressive illness:
1 . 180 660 570 531 266
2 . 164 424 411 168 159
O • 9 /, 264 320 300 31
4 8 6 186 186 1 2 0 116
5. 188 2.10 440 286 134
6 . 2 1 0 318 306 215 51
7 . 184 164 384 216 108
* the percentage difference between peak and baseline
prolactin concentrations.
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Tab1 e 4/ 1 (continued) 
Patients with PVFS:
No baseline 1 o Q difference
1 . 2 2 0 550 340 350 150
O 2 0 0 820 400 2 2 0 192
o'J . 8 8 890 370 2 1 0 911
4. 140 680 350 2 1 0 385
r; 150 780 390 2 2 0 420
6 . 89 230 2 1 0 180 158
7 . 180 950 600 320 427
8 . 1G0 1300 850 670 712
9 . 300 1740 900 490 480
-  1 0 0  -
Table 4/2
Prolactin response (mU/L) to 60 mgs of buspirone in 6 
healthy females, 6 female patients with primary 
depression and 6 female patients with PVFS:
Nc baseline 1J- 3h r s dif f
He a1 1hy females:
1 . 180 400 420 360 133
2 . 160 680 684 540 327
3. 80 556 550 424 595
4. 290 1590 1386 1 1 1 1 448
5. 2 0 0 660 556 486 230
6 . 2 2 0 4 61 492 451 123
Pat ients with p r i m a r y d e p r e s sion:
1 . 155 557 387 385 259
<•> 1 1 2 386 386 299 244
3. 280 684 681 493 144
4. 264 1268 1118 760 3S0
5. 298 584 580 410 95
6 . 256 1376 1300 720 437
'* the percentage difference between peak and baseline 
prolactin concentrations
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T ab1e 4/ 2 (continue d)
F e m a .1 e p a t i e n t; s wi t h P V F S :
No baseline 1 o 3 hrs difference
1 . 350 3060 .1140 940 774
o 360 5300 3310 1134 1 1 0 0
3. 160 1 2 1 0 820 390 656
4. 290 1980 650 320 582
5. 180 2 0 0 0 1070 540 1 0 1 1
6 . 620 2520 1 2 1 0 630 306
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Table 4/3
summary statistics - mean (standard deviation) of 
prolactin response to 60 nip s of buspirone in healthy 
subjects, patients with depressive illness and patients 
with PVF3:
TV) «■*» J »iiaico •
ni *i line
baseline
1 hr
2 hrs
3 hrs
% differ 
Females:
baseline
1 hr
2 hrs
3 hrs
% differ
healthy subj 
163 (49)
392 (110)
401 (116)
317 (132)
163 (49)
healthy subj 
188 (69)
725 (438)
681 (356)
562 (276)
309 (186)
depressive: 
179 (48) 
318 (175) 
373 (120) 
262 (134) 
.123 (77)
depressive;
227 (75) 
809 (410) 
742 (384.) 
511 (188) 
260 (131)
PVFS 
.178 (65) 
882 (434) 
490 (240) 
318 (164.) 
426 (256)
PVFS
326 (166.) 
2678 (1425) 
1367 (975) 
659 (318) 
738 (292)
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Table 4/4
One-way analysis of variance of baseline prolactin 
values and the percentage diffrence between peak and 
b ase1 ine prolactin c o n c e ntration i n he a1 1 hy subjects, 
patients with depressive illness and patients with PVFS.
DF SS MS F P
Baseline .2 1240 620 0.17 0.848
% differ 2 444079 222040 7.29 0.004
Females:
baseline 2 6.1008 30504 2.40 0.125
% differ 2 828671 414336 9.07 0.003
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Figure 4/1
-1
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cIM
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320 1
Time in hours
Prolactin response to 60mg of buspirone in 6 females 
with PVFS (—o—) and an equal number of healthy 
subjects (—x— ) and patients with primary depression
HH.
Points and bars represent mean and 95% confidence 
intervals.
Figure 4/2
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Prolactin response to 60mg of buspirone in 9 male 
patients with PVFS (—o— ) 7 healthy subjects (— * —) 
and 7 patients with primary depression (— o— ).
Points and bars represent mean and 95% confidence 
intervals.
106
b) Water metabolism in patients with PVFS: 
i: total body water and potassium:
The raw data of the total body water and potassium 
content in patients with PVFS and the predicted values 
are given in table 4/5 and 4/6.
The total body water for the group of patients with PVFS 
was 5. 3% higher than predict.ed, however, no individua 1 
result fell outwith the normal range of 84-116% of the 
predicted value. Because the predicted total body water 
values (TBW) depend on body weight which will increase 
with water retention, expressing the measured TBW as a 
percentage of the predicted TBW underest imat.es water 
r e t e n t i o ri b y a b o u t 3 0 % .
The mean total body pot.assuim was 9% lower than 
predicted, with one result falling outwith the normal 
range, i.e. 84-116% the pred ic ted value.
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Table 4/5
Measured and predicted total body water (TEW) content in 
nine patients with PVFS:
Patient height weight total TBW % predicted TEW7
(age/sex) (cm) (kg) (litres)
36M 169.5 67 .0 37.5 107
ISM IS 4.0 65.5 43.5 1 0 1
57M 176.5 76.6 42.1 104
27M 168.5 72.4 45.0 108
37 F 150.5 51.9 27.0 107
23F 169.5 SI. 9 3 5 3 114
4b F 159.0 49. 1 27. 1 103
44 F 159.0 n o. Au'._i. a 36. 5 104
27 F 162.5 P. o o ■J . o 30. 9 .107
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m  V. T ,1 / p  
j. A I: - '•!/ O
Measured and predicted total body potassium content in 
nine patients with PVFS
Patient height weight TDK % predicted TBK
(age/sex) (cm) (kg) (mmol)
6 SM 109.5 67.0 2663 8 8
19M 184.0 65.5 3507 87
57M 176.5 76.6 2914 81
27M 168.5 72.4 3763 105
37F 150.5 51.9 1850 09
23F 169.5 Cl.9 2761 99
45F 159.0 49.1 1844 65
44 F 1,59.0 36.4 2445 90
27F 152.5 52.3 2625 107
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1.1: total body water content in female patients with
PVFS with severe symptoms of fluid retention
As shown in the table below (table 4/7)„ the total body 
water content was greater in the luteal phase of the 
menstrual cycle than in the follicular phase in both 
patients. In one patient it was possible to measure the 
intracellular and extracellular water distribution in 
both phases of the menstrua] cycle. In this patient the 
i n t r aco1lu1ar water content was 91% of the predicted 
value in follicular phase of menstruation and 1 .1 1% of 
the pred i cted va1ue in the 1utea1 phace.
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Table 4/7
Total body water (TBW) and extracellular (ECW) and 
intracellular water (IGW) content in two patients with 
PVFS who exhibited severe symptoms of fluid retention 
during the follicular and the luteal phases of the
mens trual eye ie:
Patient 1
Fell i c u 1 a; i r>h a s o luteal phase
me curcxd % predicted mea sure: d % predicted
TEW 35 . 0 L 94% o o .<■>O  L) m O L 1 0 2 %
ECW 13 1. X L 97% 17. 6 L 93%
n O IS . 9 L 91% 20.9 L 311%
Pat ient 2
TEW O O .7 r.U n oo/CJ 33.6 L 06%
ECW 16.2 L
ICW 16.5 L
CjQ/y
95%
arginine vasopressin secretion in patients with
PVFS
All patients and control subjects completed this part of 
the study satisfactorily. Nausea or vomiting was not 
reported and blood pressure remained unchanged 
t h rough out t he te st.
Baseline blood urea and electrolytes and blood glucose 
were normal in all patients and controls. The urine and 
plasma osmolality and the corresponding plasma AVP 
concentrations during the water loading and the water 
deprivation tests in patients and healthy controls are 
given in tables 4/8 - 4/11 and are graphically shown in 
figures 4/3 and 4/4.
These results show that AVP values were significantly 
lower in patients with PVFS when compared with healthy 
control subjects. The mean + standard error of the mean 
(SEM) in control subjects was 0.9 ± 0 . 2  pmol/1, whereas 
the corresponding values for patients with the PVFS were 
0.1 +. 0.03 pinol/i (Student's t test, p ~ 0.001).
Furthermore, there was also a clear difference between 
the two groups during the water loading and water 
deprivation tests.
As shown in figures 4/3 and 4/4 the plasma AVP levels 
correlated with the serum and urine osmolality in 
healthy contraIs. However, the plasma AVP values in
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patients with PVFS were consistently low at high urine 
and pi asma osmolality concentrations. This suggests 
either a global deficit of AVP secretion or an abnormal 
hypothalamic response to osmotic stimuli in patients 
with. PVFS (see discussion).
rpj.-) v, i 4 /g
Urine and plasma os:molality (mrrici/kg) and tin
correspending plasma arginine-vasopressin (AVP
concent ration (pmol/1 ) in nine pat ients with PVFS dur in,
the water l.o ading test
Patient/t ime Id a s e 1 i n 0 1 2 O 4 hrs
i - urine 440 2 2 0 95 83 107
plasma. t 282 283 283 287
AVP 0 . 03 0.03 0.25 0.03 0.06
O urine 758 183 62 103 401
P1 asma 282 286 286 285 %
a  17 r>
t \ '/ i. 0.27 0 .04 0 .04 0 . 2 0 0. 17
o
v_J . u r i n c 905 178 6 6 78 271
p 1 a sma 280 O  O  Ac* LJ 'i 283 283 *
AVP 0.33 0.29 0.28 % 0.13
4. urine 840 759 116 87 178
plasma 281 282 2 8 6 282 %
AVP 0.28 0.29 0 . 2 0 . 16 0.03
p .
kJ  • urine 509 280 64 125 438
plasm.0. t 278 283 287 288
AVP 0.06 0 .06 0 .04 0 . 1 0 . 1
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/ p  f T-, -s- : v-,, ■ , ,o \
/ u  v L u I i U J . l J U ^ U  )
Patient/time baseline 1 2  3
6 . urine 727 201 46 46
plasma 276 273 232 283
AVP * 0.17 0.31 0.17
7. urine 496 575 87 73
1 ^  w  ^  ^ O  O  A  O  P  P  P  P  P
Jp XUX'-m;! ex ,iU‘s u - U U  ^.,uZ
AVP 0.12 0.25 0.25 0.14
3. urine 431 400 73 64
Plasma * 231 284 237
AVP 0.03 0.38 0.10 0.18
0. urine 690 724 310 241
plasma * 278 276 275
AVP 0.20 0.24 0.14 0.10
0.22
178
288
%
202 
2 8 7 
0.01
299
n y o
0.03
Table 4/3
Urine and plasma osmolality (mmol/kg) and the 
corresponding plasma arginine-vasopressin (AVP) 
concentration (pmol/1 ) in eight, healthy control subjects 
during the water loading test
hrs•Subject./t line baseline 1-i. O Oo
± . urine o / p<_) a O 7 0 6 8 2 3 0
plasma O P R 2 7 9 o 7 5 2 8 0
AVP 1 . 6 1 0 . .1 6 0 . 0 3 0 . 2 5
urine 1039 128 2 2 1 703
plasma 287 281 273 2 0 0
AVP 1. 44 0 . 1 1  * 0 .29
*
278
t &
3. urine 517 73 120 238 *
plasma 287 283 231 282 281
AVP 1.04 0.23 0.08 0.04 0.17
4. urine 683 103 71 81 *
plasma 277 274 270 272 275
AVP 1.49 * 0.11 0.04 0.19
5. urine 505 63 74 312 *
plasma 284 278 277 280 282
AVP 0.19 * 0.05 0.08 0.23
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Table 4/9 (continued)
Subject/1 imo baseline 1 2 3 4 hr:
6 . urine 705 116 63 94 *
plasma 282 275 271 273 283
AVP 1.07 0.34 0.5 0.29 0.27
7. urine 720 176 78 79 2 0 2
plasma 283 9 7 5 275 277 277
AVP 0.12 0 . 0 2 0 . 0 1 *
urine 1173 
plasma 283 
AVP 0.96
69
283 209
277
277
0.11 0.04 0.17 0.27
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Table 4/10
Urine-1 and plasma osmolality (mmol/kg) and the 
c o r r e s p ondi n g p .1 a s m a a rginin e-vas o p r e s sin (pm ol/l) in 
nine patients with PVFS during the water deprivation
test
Pat lent/tiine 09 ii 13 15 h:
1 . urine
plasma
AVP
207
288
0.03
240 
289 
0.06
424
289
0.06
637 
290 
0 . 1 0
*7 urine 
p 1 a s ii a 
AVP
813 
2 0 1  
0.27
794 
286 
0 . 0 1
400 
285 
0 . 1 2
282
285
0.06
<5 - urine
plasma
AVP
917
284 
0 . 33
687
287
0.41
787
283
0.28
703
O P P. ._U
0.19
4. urine
plasma
AVP
207
O Q O 
0 . *^8
o -1 O ^± CJ
285 
0. 38
640
■t
0.19
*
urine 221 308 514 796
plasma 288 289 290 279
AVP 0.06 0.05 0.05 0.11
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Table 4/10 (continued)
Patient/time 09 1 1 13 15 hr;
6 . urine 940 796 861 757
plasma 286 282 288 284
AVP * 0.26 0.26 0.26
7. urine 657 411 6 8 8 694
plasma 293 290 288 287
AVP 0.12 0.18 0.18 0.22
3. _ urine 878 306 395 291
plasma 294 296 292 290
AVP 0.03 0.32 0.26 0.44
9. urine 693 375 451 427
plasma 285 290 290 291
AVP 0.20 0.09 0.04 0.01
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Table 1/11
Urine and plasma osmolality (mmol/kg) and
corresponding AVP concentration (pmol/1) in e
healthy control subjects during the water deprive
Tub j e c t /1 1 me 11 13 15 h]
•urine
plasma
AVP
07 C
1 . GO
920
0 .S
*
230 
0.25
ur m e
Plasma
AVP
.050 904
0 . 4 2
urine
AVP
700 647
277
0 19
723 
278 
0.19
urine
p]asm,
AVP
900
277
1.20
920
0.86
789
278
0.09
617
276
o.i:
urine
AVP
684 
280 
0.18
918
o r
761
281
0.11
856
276
0.14
the 
ight 
t ion
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Subj ec 
6 .
7 .
4/11 (continued)
t./time 09 11 13 15 hrs
urine 968 705 487 318
plasma 282 280 279 280
AVP 1.01 0.69 0.18 0.31
urine * 431 679 734
plasma 1 275 277 280
AVP * 0.03 0.12 0.28
urine 286 601 799 1063
plasma 284 285 287 289
AVP 0.10 0.13 0.39 0.48
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Figure 4/3
290.0 -
Dsmol
285.0 -
280.0 -
275.0 -
•
X X
X X X  X
X X
X 0  X 
X •  X 
X XX #  )KX 
0 0 X X  
• #•* 
••
X #  x
X
•  x 0 0
0.00 0.35 0.70 1.05 1.40 1.75
AVP
Plasma AVP and the corresponding serum osmolality in 
8 healthy control subjects (•) and 9 patients with PVFS (x)
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Figure 4/4
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Plasma AVP and the corresponding urine osmaolality in 
8 healthy subjects (•) and 9 patients with PVFS (x)
E x p e r i m e n t 3: melatonin excretion in patients with PVFS
and control subjects:
The two groups were comparable in respect of age and 
total body, weight. The mean age (+ standard deviation) 
of male and female patients with PVFS was 45.0 +. 1.0 and 
35.4 4_ 4.9 years, respectively compared to 43.0 ±. 4.0 
years for males and 39.2 ± 12.6 years for females in the 
control group. Also there was no statistically 
significant difference in body weight between the two 
groups. In females the body weight (£ standard 
deviation) was 57.4 1_ 4.4 kg; in patients with PVFS and 
56.7 f_ 6.1 kg in control subjects. The mean body weight 
for male pateints and control subjects was 71.2 £ 6.7 
and 70.4 ±  10 kg, respectively.
All patients and control subjects completed the study. 
The results of urinary melatonin excretion over a period 
of 43 hours are given in tables 4/12 & 4/13.
As summarised in table 4/14 and graphically shown in 
figure 4/5, the 4 hourly urinary excretion of 
6 -sulphatoxy melatonin was higher in patients with PVFS 
than in control subjects. However, the difference 
between the two groups did not reach statistical 
significane. The increased excretion of melatonin in 
patients with PVFS was observed throughout the day, but 
more so between mid-night and S am.
The pattern of molatonin excretion in both groups was 
the same and is similar to that observed .in healthy 
subjects with maximum concentrations late at night and 
in the early hours of the morning. However, in one 
patient with PVFS and in two control subjects urinary 
6 -sulphatoxy melatonin levels reached their peak in the 
afternoon.
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Urinary melatonin excretion (ng/ml) over 48 hours period 
in 8 patients with PVFS:
Patient day 0 - 4 4 — 8 O 1 oo — j. ^ 1 2 - 1 6 1 6 - 2 0 9 Q 9,
1 - 2 4 . 9 1 6  P 0 . 9 2 . 5 _
o - - 1 3 . 0 _ 9 7£_J { -
2 1 - O -' .I o £4\j * O 1 7  .9 4 . 0 2 . 8 7 . 7
_ o o  nt 1 3 . 0 o oO . -i- 0 . 1 3 .8
O 1 . X ~ 1 .6 1 1 . 1 2 . 1 2 .3 3 . 5
f'f o n o oX. * 1 . 6 7 .7 2 1 . 1 4 . 3
4 1 - “ - 1 . 9 1 . 8 1 4 . 3
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Tabic 4/14
Summary statistics: 24 hour urinary melatonin excretion 
(n g / m l ) in 3 patients with PVFS and 6 control subjects. 
The values represent the mean + standard error of the
Hi 0 ci n.
0-4 4-3 8-12 12-16 16-20 20-24
PVFS 11.3+4.2 18.3±3.9 9.0+2.0 3.5+1.0 5.1+2.5 5.1+1.3
Cont.7.6+2.7 10.7+2.9 9.3+4.8 2.8+0.6 3.9+1.2 2.9+1.0
P " 0.6 0.1 0.9 0.6 0.7 0.2
\
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24 hour urinary melatonin excretion (ng / ml) in 8 patients with 
PVFS ( —°—) and 6 control subjects (—•— ). Values represent 
mean ± SEM
I
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CHAPTER FIVE
DISCUSSION AND SUMMARY
1 oO
Discuss ion:
There- are a number of reasons for studying hypothalamic, 
function in patients with PVFS. First, the hypothalamus 
controls circadian rhythms, food intake, fluid balance, 
gut motility temperature regulation and cardiac 
function. All of these are affected in patients with 
PVFS. Secondly, the hypothalamus influences mood, drive 
and behaviour (see pages 61-68). Central fatigue, i.e. 
fatigue which is not the result of structural muscle 
disease or abnormal ities of neuromuscular transmission, 
is the core feature of this syndrome and is due to lack 
of drive. Thirdly, the hypothalamus plays an important 
role in consolidation of short term memory, emotional 
expression, adaptation to stress and immune regulation. 
As described in chapter one, depressed mood, anxiety, 
hypochondriasis and poor short term memory are 
frequently encountered in patients with PVFS. 
Immunological abnormalitiics have been documented in 
these patients (Caligiuri et al 1987, Morrison et al, 
1991). Finally, whilst postmortem studies have not been 
conclusive, they suggest hypothalamic involvement in 
these patients (see chapter two). We, therefore, 
undertook the present study, which is the first formal 
evaluation of hypothalamic function in patients with 
PVFS.
In the first part of the study, we used a neuroendocrine 
challenge test to see if there was increased
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sensitivity of hypothalamic 5-HT receptors (which 
suggests depletion of 5-HT in these patients). We then 
studied water metabolism, including measurements of 
total body water content and arginine-vasopressin 
release in response to water deprivation and water 
loading- Finally, we measured melatonin excretion in 
these patients.
In the first study wo demonstrated a significantly 
increased prolactin response to buspirone challenge in 
patients with PVFS in comparison with healthy 
individuals and also with patients suffering from 
primary depressive illness. As discussed earlier (see 
pages 69-71), prolactin response to buspirone 
administration appears to be mediated via hypothalamic 
5-HT receptors. The findings of the present study, 
therefore, suggest an increased sensitivity. of central 
5-HT receptors in patients with PVFS.
Our results also show that there was no significant 
increase in serum prolactin levels in patients with 
primary depression following the administration of 60 mg 
of buspirone. The buspirone challenge test may, 
therefore, be a useful clinical test to differentiate 
between PVFS and major depressive illness.
The use of neuroendocrine challenge tests to assess the 
hypothalamic function has now become a standard research 
method in biological psychiatry and is widely used in
1 o n  
_  lOo ~
the assessment of hypothalamic function in patients
with a variety of psychiatric disorders, including panic 
disorder (Kahn et al, 1988) and major depressive illness 
(Cowen & Charig, 1987, Golden et al, 1990). The validity 
of the data obtained using neuroendocrine challenge 
tests has been corroborated by other methods. For 
example, decreased 5-HT mediated prolactin release has 
been demonstrated in patients with major depressive 
illness with the 5-HT reuptake inhibitor clomipramine 
(Anderson et al, 1992) but not in response to
t h yrotr o p in-rele a s i n g h o r in one (wh i c h a c t s d irec 1 1 y o n
the pituitary to release prolactin). This suggests
decreased function of central 5-HT neurones in depressed 
patients, an observation which was confirmed in 
postmortem studies using autoradiography (Yates et al, 
1920). Heuroendocrine cha11enge te313 have a13o proved 
to be more valuable in assessing the function of the 
pituitany-hypotha1amic axis than the standard pituitary 
stimulation tests (see below).
Hypothalamic dysfunction has been suspected as a major 
pathogenetic mechanism in primary depression because 
symptoms of hypothamic disease, e.g. change in appetite, 
body weight, sleep pattern and libido, and also 
endocrine changes, such as hypercortisol ism, increased 
corticotropin releasing hormone (which acts as a 
nourotran smit/ter in the limbic system and cerebral 
cortex) and the blunted ACTH response to corticotropin 
releasing hormone (Sachar et al, 1970, Amsterdam et al.
- ids -
1987, Cowan & Wood, 1991) occur j n these patients. 
Deereased brain concentration; of 5-HT (which is 
involved in the regulation of hypothalamic function as 
described in chapter two) has been extensively reported 
in patients with primary depressive illness (Shaw et al, 
1967, Goodwin & Post, 1983, Co wen et al, 1987, Co wen & 
Charig, 1987). This data heralded a period of extensive 
research in psychiatry 'using routine endocrine tests, in 
particular the pituitary function tests, in an attempt 
to elucidate the pathogenetic mechanisms of mental 
illness.
However, the use of pituitary function tests (which are 
relatively cheap and easy to do) as an indirect method 
of assessing hypothalamic function in patients with 
depressive illness has resulted in contradictory and 
misleading data. This is largely because of the 
multiplicity of the feedback and feedforward mechanisms 
which regulate pituitary function. In recent years these 
tests have, therefore, been replaced by the more robust 
neuroendocrine challenge tests, such as the buspirone 
test.
In all studies we? selected patients who fulfilled strict 
diagnostic criteria of PVFS as described earlier (Behan 
1991, Eehan and Bakheit 1991 ) . A 11 patients have had 
fatigue and other symptoms for more than S months. The 
onset of their symptoms followed a viral illness and 
conditions such as chronic infection, malignancy etc,
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v/hioh can cause chronic fatigue and lassitude have been 
excluded. The patients had a well-adjusted premorbid 
personality as suggested by their previous ability to 
cope with every day stress and had good work records. 
None of the patients had a past or family history of 
psychiatric illness. Primary depression can of course 
occur de novo in individuals with a previously 
well-adjusted premorbid personality and a good family 
history, but the depressive symptoms in our patients 
wore different from those:1 which occur in primary 
depression (Behan & Bakheit, 1991, Procter, 1991). For
example, none of cur patients expressed feelings of 
guilt, self-depreciation or had anhedonia.
In addition to the typical clinical features of PVFS in 
the patients solooted for this study, the organic nature 
of their symptoms was supported by the presence of the 
oharacteristic mitochondria 1 dair,age previously reported 
in patients with the PVFS (Gow & Behan 1991, Behan et 
al, in press) and the presence of enteroviral genomic 
KNA in muscle biopsy (Gow et al, 1991).
In this study we also carefully controlled for factors 
which affect prolactin secretion. One of these factors 
is the influence of female sox hormones on prolactin 
release. The variability of buspirone-induced prolactin 
release during the various phases of the menstrual cycle 
are well documented. Yatham et al (19B9) studied the 
pro1 noain responses to a single oral dose (60 mgs) of
buspirone In 6 lienithy women during the follicular and 
luteal phases (defined as day 2 and day 24 of the 
menstrual cycle, respectively) and also at mid cycle 
(day 14). These authors found a significantly higher 
prolactin response in the luteal phase of the menstrual 
cycle than at mid cycle or in the follicular phase. 
Similar observations were confirmed by Dinan et al 
(1990) .
We took two measures to overcome the possible bias due 
to the effects of female gonadal hormones on prolactin 
secretion. First, data for males and females were 
analysed separate.1 y . Second 1 y , a 1.1 fema 1 e patients (who 
were menstruating normally) were studied in the luteal 
phase of the menstrual cycle.
From our results it can be seen that, in contrast to 
patients with PVFS, those suffering from primary 
depressive illness had a blunted prolactin response to 
buspirone. This finding is in agreement with the results 
of a recent study (Upadhyaya et a], 1991) and indicates
a fundamental difference in central 5-HT receptor 
function between patients with PVFS and those, suffering 
from primary depressive illness. In , the study of 
Upadhyaya and colleagues the prolactin response to drugs 
wh i ch i nc r e ase 5-HT cone ont r at i on s in brain, e.g. 
L-tryptophan, clomipramine and fenfluramine, was found 
to be reduced. Interestingly, the normal response was 
restored with the successful treatment of depression.
1  o  L> —
For this reason buspirone challenge test may be useful 
in. the differential diagnosis of these two conditions.
In contrast to our findings, at. least two studies have 
reported significantly higher baseline serum prolactin 
values, in depressed patients than in healthy controls
(Go1don ot a1, 1989, Wh a11e y et a1 1989). Int e rest i ng 1y ,
despite the raised baseline prolactin values observed 
in depressive patients, the response to the 5-HT 
inhibitor clomipramine in these studies (Golden et al, 
1989, Anderson et al, 1992) was. identical to that seen 
i n o u v p a t i. e n t s .
V7ha 11 ey et al. (1989) measured the plasma concentration
of prolactin in 98 psychotic patients and 35 healthy 
control subjects over a period of 17 hours and found 
significantly increased serum prolactin concentrations 
in patients with sohizoaffectivc mania and psychotic 
depression, especially in morning blood samples. 
However, 32 of these patients received neuroleptic or
sedative drugs prior to admission and 30 of the 
remaining patients were given amylobarbitono on the day 
of blood sampling because of behavioural problems. The 
discrepancy between our results a,nd those of Whalley et 
al (1989) can be* accounted for by methodological 
artefacts in their study. First, these authors
studied patients on their first admission to a 
psychiatric unit. It is usually difficult to make a 
definitive diagnosis of depressive illness on the
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patients'' first admission to hospital. The diagnosis of 
depressive illness, for exampl e , may be changed to 
schizophrenia at a later date. Secondly, in this study 
patients were receiving antipsychotic medication during 
the study. Almost all of these drugs are known to 
interfere with brain neurotransmitters and 
ne u ro peptides which regu1 at e hypotha1am ic~pitu i ta ry
function.
In conclusion, in this study we have shown that patients 
with PVFS have a significantly higher prolactin response 
to buspirone challenge when compared with healthy 
subjects and patients with primary depression. This 
suggests upregulation of hypothalamic 5-HT receptors.
Because of the clear difference in prolactin response 
between patients with PVFS and depressives the buspirone 
challenge test can be exploited as a diagnostic test to 
differentiate between these two conditions.
In our next experiment we measured the total body water 
content in a well-defined group of patients with PVFS. 
He also measured the total body water content and the 
volume of the intracellular and extracellular fluid 
compartments in the luteal and follicular phases of the 
menstrual cycles in two female patients with this 
disorder who also exhibited features identical to those 
of the fluid retention syndrome. For further evaluation 
of the hypothalamic-pituitary regulation of water
metabolism wo studied the secretion of AVP in response 
to plasma and urine osmolality changes during the water 
loading and water deprivation tests.
Our results showed that patients with PVFS have an 
increased total body water content when compared with 
the predicted values in age? and sex-matched healthy 
centred, subjects. The mean total body water in patients 
was 5.3% higher than that in controls. Because total 
body water values depend on body weight which will 
increase with water retention, expressing the total body 
water as a percentage of the predicted values 
underestimates water retention by about 30%. Patients 
w ith 15/ F S , t h e r e f o r e , hi a v e a s i g n i f i. c a n 1 1 y hi i gb e r t o t a 1 
body water than healthy subjects.
We studied two women with PVFS and signs of fluid 
retention which always became worse in the preovulatory 
phase of the menstrual cycle. In these patients the 
total body water and the intracellular water content 
were signif icantly greater in the luteal than in the 
f o 1 lie u 1 a r ph a s e o f t h e in e n s t r u a 1 cycle.
Finally, the baseline AVP values were significantly 
lower in patients with PVFS than in healthy subjects and 
they tended to remain low at relatively high plasma and 
urine osmolality during the water deprivation test. This 
suggests either a global deficit of AVP secretion or 
sensitivity of the osmoreceptor to osmotic
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stimuli. In some patients there was no correlation 
between plasma or urine osmolality and plasma AVP 
concentrations, suggesting failure of hypothalamic 
regulation of AVP secretion.
The findings reported in this study could not have been 
due to methodologiacl artefacts. We measured the plasma 
rather than serum osmolality. This is because the 
methods used for scrum preparation may lead to apparent 
increase In plasma AVP concentrations (Redefcski et al, 
1972). Similarly, venous stasis was avoided when blood 
samples for osmolality were collectd as artefactual 
increase in osmolality by up to 2 0 mosmol/kg may result, 
from the use of a tourniquet (Robertson et al, 1976).
high blood urea and/or hyper gl ycaenii a distort the 
relationship between plasma osmolality and plasma AVP 
coiicen trations (Robertson, 1976) . All our patients had
normal blood urea and electrolytes and a normal blood 
glucose.
Nausea and vomiting, which arc potent stimuli of AVP 
release (Zcrbe & Robertson, 1987), were not reported by 
either the patients or the control subjects.
We wore also careful to control for all the other 
factors which influence AVP release. These are cigarette 
sucking (Rowe et al, 1980) , the effects of posture,
hypovolacmia and the phase of the menstrual cycle.
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Tmoking was not allowed during the study. The tests were 
carried out with the patients and control subjects lying 
down except when voiding.
Dehydration during the water deprivation test may cause 
hypovolaemia. A reduction in circulating blood volume by 
7-15% is a strong stimulus of AVP release (Robertson & 
Athar 1976). However, such a large decrease in 
c i r c u 1 a. t i n g b I o o d v o 1 urn e ine v .i t ab 1 y t r igge r s
compansotary mechanisms, e.g. tachycardia, and is 
accompanied by a fall in arterial blood pressure. All of 
our patients and control subjects had a stable blood 
pressure and pulse rate throughout the study. We can, 
therefore, safely assume that there was no significant 
decrease in blood volume in these subjects.
The hypothalamic-pituitary response to the various 
stimuli which inhibit or trigger AVP release varies 
according to the phase of menstrual cycle and is thought 
to be due to the effects of female sex hormones. The 
basal plasma osmolality and the osmotic threshold for 
thirst and AVP release were found to be significantly 
lower in the luteal than in the follicular phase of the 
menstrual cycle (Spruce et al, 1985). However, the 
normal correlation between plasma osmolality and plasma 
AVP concentration is preserved in both phases of the 
menstrual cycle. In one study (Spruce et al. .1985) the 
correlation coefficient between p]asma osmolality and 
AVP values was 0.95 in the luteal rhase and 0.93 in the
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follicular phase. To eliminate the possible effects of
female gonadal hormone variations In the different 
phases of the menstrual cycle on AVP release all female 
patients were studied in the luteal phase of the cycle.
In this study we chose? to use water loading and water 
deprivation rather than saline infusion to induce plasma 
osmolality changes because, as stated by Hammer et al 
(1980 ) , f1uid deprIvation is thc natura1 phyaio1ogica1 
stimulus for AVP release and also because it does not 
in tor for with other systems 'which regulate renal 
function, e .g. the renin-angiotensin-aldosterone system.
Although hospital i sa t i on and fasting for the tost may 
cause some degree of emotional stress in some patients, 
stress per se has no effect on AVP release. Experimental 
ovid cnce in hea 1.thy subj ects (Edelson et cx 1 , 1986) and
also in patients with anxiety neurosis (Raskind et al, 
1978) shows that stress increases AVP release only when 
it is accompanied by nausea or hypovo1aemia.
One of the findings in this study, namely the delayed 
excretion of a water load, has been previously reported 
in 1 0 out of 33 patients with "chronic nervous 
exhuasticn" (Levy et al, 1948). These patients were 
described as having " a definite reduction of vigour if 
not loss of strength" as their main presenting symptom. 
Although the authors do not mention a history of a viral 
illness preceding the symptoms of fatigue in these
patients, their description of the disorder which they 
named chronic nervous exhaustion fits the diagnosis of
j; v
In conclusion, this study has shown that patients with 
PVFG have an increased total body water content, 
deficiency of AVP secretion and an erratic AVP response 
to osmotic stimuli. Taken together with our observation 
of an increased prolactin response to buspirone in these 
patients, these abnormalities of water metabolism 
suggest hypothalamic dysfunction in patients 'with the 
PVFS.
Finally, we measured the melatonin excretion over a 48 
hour period in patients with PVFS and a group of control 
subjects. Analysis of our data shows that patients with 
PVFS excreted more O-sulphatoxy melatonin than the 
oontrol subjects , especia1 1 y between mid night and 8 am. 
However, the difference did not reach the level of 
statistical significane. An important finding in this 
study is that the pattern of melatonin excretion in 
patients with PVFS and control subjects was the same 
with peaks early in the morning and low values in the 
afternoon. This profile is similar to that reported in 
healthy subjects (Wetterberg, 1978) and was seen in all 
patients with PVFS except one.
Age, sex and body weight have important effects on 
pineal function (Ferrier, 1982, Iguchi et al, 1982). To
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eliminate the effects of these factors patients with 
PVFS in this study were carefully matched for these 
parameters with control subjects.
One can not draw hard conclusions from this part of the 
study, of small sample. However, the observed 
differences between patients with PVFS and control 
subjects suggest a possibility of melatonin disturbances 
in these patients.
d) Summary and concluding remarks:
The clinical features of PVFS suggest hypothalamic 
dysfunction in these patients. The role of the 
hypothalamus in regulating food intake, fluid balance, 
temperature regulation, gut motility, cardiovascular, 
sexual and endocrine functions is well-documented.
5-HT is the main neurotransmitter in the hypothalamus 
and abnormalities of 5-HT secretion may underlie 
hypothalamic dysfunction. Disoders, such as migraine and 
the fluid retention syndrome, in which disturbances of 
central 5-HT are known or suspected to play an important 
role are common in patients with PVFS. Patients with 
PVFS often have symptoms identical to those of the 
irritable bowel syndrome. Recent evidence suggests that 
the latter disorder may be due to hypersensitivity of 
hypothalamic 5-HT receptors (Dinan et al, 1990). We have 
seen several patients with PVFS who developed craving
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for chocolates and sweets following the onset of their 
illness. The basis for this curious symptom of craving 
for c arbohydr a t c o is thought to be an abnormality of 
central 5-HT regulation (Wurtman & Wurtman, 1989).
In the present study we have shown upregulation of 
hypothalamic 5-HT receptors in those patients and subtle 
abnormalities in hypothalamic regulation of water 
metabolism in patients with PVFS. The persistence of 
enteroviral genomic RNA particles in skeletal muscle of 
more than 50% of patients with PVFS studied ana 
structural abnormalities of muscle mitochondria have 
been reported (Gov et al, 1991, Gow & Behan, 1991)). It 
Is possible that similar changes are also present in the 
hypothalamus of these patients.
The association of PVFS with poliomyelitis has also been 
extensively reported (see review7 of epidemics of PVFS) 
and may be an important clue in the aet.iopathogenesis 
of PVFS. Hypothalamic involvement may occur in patients 
vJith poliomyelitis where there are subtle disturbances 
of temperature regulation, gut motility and sexual 
fi 3 n c t i o n (B a k e r e t a 1, 19 50) . I n a d d i t i o n , t h e s e
patients often have sleep disturbances and emotional 
lability. Similar observations were reported by Brown et 
al. (1947) in their description of patients dying of 
poliomyelitis.
Hypothalamic dysfunction is also known to occur in
- 1 4 5
patients with mitochondrial disease (Fitzsimons et al, 
1981, Herzberg, 1990). Of great interest is recent work 
showing that viruses and other microorganisms can cause 
subtle hormonal and neurotransmitter abnormalities in 
the hypothalamus without producing local structural 
damage. For example, although trypanosomes, which cause 
African sleeping sickness with fatigue; and endocrine 
d.j. sturbances, do not cross the b 1 ood-brain barrier, thoy 
can cause selective induction of MHC class I in 
hpothalamic neurones in the early stages of the disease 
(K r i s t en s son, 1990).
Oldstone and colleagues (0 1 dstone et a1 , 1984, 0 1 dstone, 
1989, de la Torre et al, 1991) have demonst r ate d 
conclusively that viruses may interefere with the 
production of hormones, neurotransmi1.1 ers and cytokines 
without causing cell lysis. This is of great importance 
in considering the fact that no morphological evidence 
of hypothalamic damage has been seen in some cases of 
PVFS examined at postmortem (personal communication: Dr 
J. MeLaughland)).
The raphe nuclei (and 5-HT systems) are particularly 
susceptible to viral infections. Infection of rats with 
viruses via the nasal mucosa causes alteration in 
central 5-HT concentrations and behavioural changes in 
these animals (Kristensson, personal communication). It 
is worthy of note that these bioehemica1 and behavioural 
changes in these animals may persist for many months.
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y;hile the cellular infiltrate in the hypothalamus
are two weens a
the studies discussed in this thesis 
do3rion3 t.rs.t3 subtle abnormalities of hypothalamic 
function and v pregu1at ion of hypothalamic 5-HT receptors 
in pati ents with PVFS. Taken together with the evidence 
that enterovirus persistence has been established In the 
muscle of patients with this disorder, and that 
p e r 3 i s t e n t v i r u s e s can i n t e r f e r e w i t h cel. 1. f u n c 1 1. o n 
without causing cel1 death, we postulate that the 
no 11 r o o n d o c r i n o a n d 5 - •H T a b n o r ni a I i t i c s r c p o r t e d h ore a r e 
due to viral persistence in hypothalamic neurones. Wo 
are at present attempting to establish an animal model 
of persistent enteroviral infection in the nervous 
system, to tost this hypothesis.
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